1
|
Centonze G, Natalini D, Grasso S, Morellato A, Salemme V, Piccolantonio A, D'Attanasio G, Savino A, Bianciotto OT, Fragomeni M, Scavuzzo A, Poncina M, Nigrelli F, De Gregorio M, Poli V, Arina P, Taverna D, Kopecka J, Dupont S, Turco E, Riganti C, Defilippi P. p140Cap modulates the mevalonate pathway decreasing cell migration and enhancing drug sensitivity in breast cancer cells. Cell Death Dis 2023; 14:849. [PMID: 38123597 PMCID: PMC10733353 DOI: 10.1038/s41419-023-06357-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Revised: 11/09/2023] [Accepted: 11/30/2023] [Indexed: 12/23/2023]
Abstract
p140Cap is an adaptor protein involved in assembling multi-protein complexes regulating several cellular processes. p140Cap acts as a tumor suppressor in breast cancer (BC) and neuroblastoma patients, where its expression correlates with a better prognosis. The role of p140Cap in tumor metabolism remains largely unknown. Here we study the role of p140Cap in the modulation of the mevalonate (MVA) pathway in BC cells. The MVA pathway is responsible for the biosynthesis of cholesterol and non-sterol isoprenoids and is often deregulated in cancer. We found that both in vitro and in vivo, p140Cap cells and tumors show an increased flux through the MVA pathway by positively regulating the pace-maker enzyme of the MVA pathway, the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), via transcriptional and post-translational mechanisms. The higher cholesterol synthesis is paralleled with enhanced cholesterol efflux. Moreover, p140Cap promotes increased cholesterol localization in the plasma membrane and reduces lipid rafts-associated Rac1 signalling, impairing cell membrane fluidity and cell migration in a cholesterol-dependent manner. Finally, p140Cap BC cells exhibit decreased cell viability upon treatments with statins, alone or in combination with chemotherapeutic at low concentrations in a synergistic manner. Overall, our data highlight a new perspective point on tumor suppression in BC by establishing a previously uncharacterized role of the MVA pathway in p140Cap expressing tumors, thus paving the way to the use of p140Cap as a potent biomarker to stratify patients for better tuning therapeutic options.
Collapse
Affiliation(s)
- Giorgia Centonze
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Dora Natalini
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Silvia Grasso
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Alessandro Morellato
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Vincenzo Salemme
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Alessio Piccolantonio
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Giacomo D'Attanasio
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Aurora Savino
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Olga Teresa Bianciotto
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Matteo Fragomeni
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Andrea Scavuzzo
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Matteo Poncina
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Francesca Nigrelli
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Mario De Gregorio
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Valeria Poli
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Pietro Arina
- UCL, Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, WC1E 6BT, London, UK
| | - Daniela Taverna
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Joanna Kopecka
- Department of Oncology, University of Torino, Italy; Molecular Biotechnology Center, Piazza Nizza 44, 10126, Torino, Italy
| | - Sirio Dupont
- Department of Molecular Medicine (DMM), University of Padova, Padua, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Chiara Riganti
- Department of Oncology, University of Torino, Italy; Molecular Biotechnology Center, Piazza Nizza 44, 10126, Torino, Italy.
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126, Torino, Italy.
| |
Collapse
|
2
|
Krane N, Turco E, Bernhardt A, Jacob D, Gandus G, Passerone D, Luisier M, Juríček M, Fasel R, Fernández-Rossier J, Ruffieux P. Exchange Interactions and Intermolecular Hybridization in a Spin- 1/ 2 Nanographene Dimer. Nano Lett 2023; 23:9353-9359. [PMID: 37819646 DOI: 10.1021/acs.nanolett.3c02633] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/13/2023]
Abstract
Phenalenyl is a radical nanographene with a triangular shape hosting an unpaired electron with spin S = 1/2. The open-shell nature of the phenalenyl is expected to be retained in covalently bonded networks. As a first step, we report synthesis of the phenalenyl dimer by combining in-solution synthesis and on-surface activation and its characterization on Au(111) and on a NaCl decoupling layer by means of inelastic electron tunneling spectroscopy (IETS). IETS shows inelastic steps that are identified as singlet-triplet excitation arising from interphenalenyl exchange. Spin excitation energies with and without the NaCl decoupling layer are 48 and 41 meV, respectively, indicating significant renormalization due to exchange with Au(111) electrons. Furthermore, third-neighbor hopping-induced interphenalenyl hybridization is fundamental to explaining the position-dependent bias asymmetry of the inelastic steps and activation of kinetic interphenalenyl exchange. Our results pave the way for bottom-up synthesis of S = 1/2 spin-lattices with large exchange interactions.
Collapse
Affiliation(s)
- N Krane
- nanotech@surfaces Laboratory, Empa - Swiss Federal Laboratories for Materials Science and Technology, Ueberlandstrasse 129, 8600 Dübendorf, Switzerland
| | - E Turco
- nanotech@surfaces Laboratory, Empa - Swiss Federal Laboratories for Materials Science and Technology, Ueberlandstrasse 129, 8600 Dübendorf, Switzerland
| | - A Bernhardt
- Department of Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
| | - D Jacob
- Departamento de Polímeros y Materiales Avanzados: Física, Química y Tecnología, Universidad del País Vasco UPV/EHU, Av. Tolosa 72, E-20018 San Sebastián, Spain
- Basque Foundation for Science, IKERBASQUE, Plaza Euskadi 5, E-48009 Bilbao, Spain
| | - G Gandus
- Integrated Systems Laboratory, ETH Zürich, Gloriastrasse 35, 8092 Zürich, Switzerland
| | - D Passerone
- nanotech@surfaces Laboratory, Empa - Swiss Federal Laboratories for Materials Science and Technology, Ueberlandstrasse 129, 8600 Dübendorf, Switzerland
| | - M Luisier
- Integrated Systems Laboratory, ETH Zürich, Gloriastrasse 35, 8092 Zürich, Switzerland
| | - M Juríček
- Department of Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
| | - R Fasel
- nanotech@surfaces Laboratory, Empa - Swiss Federal Laboratories for Materials Science and Technology, Ueberlandstrasse 129, 8600 Dübendorf, Switzerland
- Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Freiestrasse 3, 3012 Bern, Switzerland
| | - J Fernández-Rossier
- International Iberian Nanotechnology Laboratory (INL), Avenida Mestre José Veiga s/n, 4715-330 Braga, Portugal
| | - P Ruffieux
- nanotech@surfaces Laboratory, Empa - Swiss Federal Laboratories for Materials Science and Technology, Ueberlandstrasse 129, 8600 Dübendorf, Switzerland
| |
Collapse
|
3
|
Salemme V, Centonze G, Avalle L, Natalini D, Piccolantonio A, Arina P, Morellato A, Ala U, Taverna D, Turco E, Defilippi P. The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity. Front Oncol 2023; 13:1170264. [PMID: 37265795 PMCID: PMC10229846 DOI: 10.3389/fonc.2023.1170264] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Accepted: 04/28/2023] [Indexed: 06/03/2023] Open
Abstract
Breast cancer is a highly heterogeneous disease, at both inter- and intra-tumor levels, and this heterogeneity is a crucial determinant of malignant progression and response to treatments. In addition to genetic diversity and plasticity of cancer cells, the tumor microenvironment contributes to tumor heterogeneity shaping the physical and biological surroundings of the tumor. The activity of certain types of immune, endothelial or mesenchymal cells in the microenvironment can change the effectiveness of cancer therapies via a plethora of different mechanisms. Therefore, deciphering the interactions between the distinct cell types, their spatial organization and their specific contribution to tumor growth and drug sensitivity is still a major challenge. Dissecting intra-tumor heterogeneity is currently an urgent need to better define breast cancer biology and to develop therapeutic strategies targeting the microenvironment as helpful tools for combined and personalized treatment. In this review, we analyze the mechanisms by which the tumor microenvironment affects the characteristics of tumor heterogeneity that ultimately result in drug resistance, and we outline state of the art preclinical models and emerging technologies that will be instrumental in unraveling the impact of the tumor microenvironment on resistance to therapies.
Collapse
Affiliation(s)
- Vincenzo Salemme
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Turin, Italy
| | - Giorgia Centonze
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Turin, Italy
| | - Lidia Avalle
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Turin, Italy
| | - Dora Natalini
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Turin, Italy
| | - Alessio Piccolantonio
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Turin, Italy
| | - Pietro Arina
- UCL, Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London, United Kingdom
| | - Alessandro Morellato
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Turin, Italy
| | - Ugo Ala
- Department of Veterinary Sciences, University of Turin, Grugliasco, TO, Italy
| | - Daniela Taverna
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Turin, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Turin, Italy
| |
Collapse
|
4
|
Salemme V, Vedelago M, Sarcinella A, Moietta F, Piccolantonio A, Moiso E, Centonze G, Manco M, Guala A, Lamolinara A, Angelini C, Morellato A, Natalini D, Calogero R, Incarnato D, Oliviero S, Conti L, Iezzi M, Tosoni D, Bertalot G, Freddi S, Tucci FA, De Sanctis F, Frusteri C, Ugel S, Bronte V, Cavallo F, Provero P, Gai M, Taverna D, Turco E, Pece S, Defilippi P. p140Cap inhibits β-Catenin in the breast cancer stem cell compartment instructing a protective anti-tumor immune response. Nat Commun 2023; 14:2350. [PMID: 37169737 PMCID: PMC10175288 DOI: 10.1038/s41467-023-37824-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Accepted: 04/03/2023] [Indexed: 05/13/2023] Open
Abstract
The p140Cap adaptor protein is a tumor suppressor in breast cancer associated with a favorable prognosis. Here we highlight a function of p140Cap in orchestrating local and systemic tumor-extrinsic events that eventually result in inhibition of the polymorphonuclear myeloid-derived suppressor cell function in creating an immunosuppressive tumor-promoting environment in the primary tumor, and premetastatic niches at distant sites. Integrative transcriptomic and preclinical studies unravel that p140Cap controls an epistatic axis where, through the upstream inhibition of β-Catenin, it restricts tumorigenicity and self-renewal of tumor-initiating cells limiting the release of the inflammatory cytokine G-CSF, required for polymorphonuclear myeloid-derived suppressor cells to exert their local and systemic tumor conducive function. Mechanistically, p140Cap inhibition of β-Catenin depends on its ability to localize in and stabilize the β-Catenin destruction complex, promoting enhanced β-Catenin inactivation. Clinical studies in women show that low p140Cap expression correlates with reduced presence of tumor-infiltrating lymphocytes and more aggressive tumor types in a large cohort of real-life female breast cancer patients, highlighting the potential of p140Cap as a biomarker for therapeutic intervention targeting the β-Catenin/ Tumor-initiating cells /G-CSF/ polymorphonuclear myeloid-derived suppressor cell axis to restore an efficient anti-tumor immune response.
Collapse
Affiliation(s)
- Vincenzo Salemme
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
- Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy
| | - Mauro Vedelago
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Alessandro Sarcinella
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Federico Moietta
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Alessio Piccolantonio
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
- Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy
| | - Enrico Moiso
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Giorgia Centonze
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
- Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy
| | - Marta Manco
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Andrea Guala
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Alessia Lamolinara
- Immuno-Oncology Laboratory, Center for Advanced Studies and Technology (CAST), Department of Neuroscience, Imaging and Clinical Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti-Pescara, Italy
| | - Costanza Angelini
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Alessandro Morellato
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
- Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy
| | - Dora Natalini
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Raffaele Calogero
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
- Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy
| | - Danny Incarnato
- Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, Groningen, the Netherlands
| | - Salvatore Oliviero
- Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy
- Department of Life Sciences and Systems Biology, University of Turin, Torino, Italy and IIGM, Candiolo, Italy
| | - Laura Conti
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
- Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy
| | - Manuela Iezzi
- Immuno-Oncology Laboratory, Center for Advanced Studies and Technology (CAST), Department of Neuroscience, Imaging and Clinical Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti-Pescara, Italy
| | - Daniela Tosoni
- European Institute of Oncology IRCCS, 20141, Milan, Italy
| | | | - Stefano Freddi
- European Institute of Oncology IRCCS, 20141, Milan, Italy
| | - Francesco A Tucci
- European Institute of Oncology IRCCS, 20141, Milan, Italy
- School of Pathology, University of Milan, Milan, Italy
| | - Francesco De Sanctis
- Immunology Section, Department of Medicine, University of Verona, 37134, Verona, Italy
| | - Cristina Frusteri
- Immunology Section, Department of Medicine, University of Verona, 37134, Verona, Italy
| | - Stefano Ugel
- Immunology Section, Department of Medicine, University of Verona, 37134, Verona, Italy
| | - Vincenzo Bronte
- Immunology Section, Department of Medicine, University of Verona, 37134, Verona, Italy
- Istituto Oncologico Veneto, IRCCS, 35128, Padova, Italy
| | - Federica Cavallo
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
- Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy
| | - Paolo Provero
- Neuroscience Department "Rita Levi Montalcini", University of Torino, Via Cherasco 15, 10126, Torino, Italy
| | - Marta Gai
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Daniela Taverna
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
- Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Salvatore Pece
- European Institute of Oncology IRCCS, 20141, Milan, Italy.
- Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20142, Milano, Italy.
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
- Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy.
| |
Collapse
|
5
|
Angelini C, Morellato A, Alfieri A, Pavinato L, Cravero T, Bianciotto OT, Salemme V, Natalini D, Centonze G, Raspanti A, Garofalo T, Valdembri D, Serini G, Marcantoni A, Becchetti A, Giustetto M, Turco E, Defilippi P. p140Cap Regulates the Composition and Localization of the NMDAR Complex in Synaptic Lipid Rafts. J Neurosci 2022; 42:7183-7200. [PMID: 35953295 PMCID: PMC9512579 DOI: 10.1523/jneurosci.1775-21.2022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 06/07/2022] [Accepted: 06/12/2022] [Indexed: 11/21/2022] Open
Abstract
The NMDARs are key players in both physiological and pathologic synaptic plasticity because of their involvement in many aspects of neuronal transmission as well as learning and memory. The contribution in these events of different types of GluN2A-interacting proteins is still unclear. The p140Cap scaffold protein acts as a hub for postsynaptic complexes relevant to psychiatric and neurologic disorders and regulates synaptic functions, such as the stabilization of mature dendritic spine, memory consolidation, LTP, and LTD. Here we demonstrate that p140Cap directly binds the GluN2A subunit of NMDAR and modulates GluN2A-associated molecular network. Indeed, in p140Cap KO male mice, GluN2A is less associated with PSD95 both in ex vivo synaptosomes and in cultured hippocampal neurons, and p140Cap expression in KO neurons can rescue GluN2A and PSD95 colocalization. p140Cap is crucial in the recruitment of GluN2A-containing NMDARs and, consequently, in regulating NMDARs' intrinsic properties. p140Cap is associated to synaptic lipid-raft (LR) and to soluble postsynaptic membranes, and GluN2A and PSD95 are less recruited into synaptic LR of p140Cap KO male mice. Gated-stimulated emission depletion microscopy on hippocampal neurons confirmed that p140Cap is required for embedding GluN2A clusters in LR in an activity-dependent fashion. In the synaptic compartment, p140Cap influences the association between GluN2A and PSD95 and modulates GluN2A enrichment into LR. Overall, such increase in these membrane domains rich in signaling molecules results in improved signal transduction efficiency.SIGNIFICANCE STATEMENT Here we originally show that the adaptor protein p140Cap directly binds the GluN2A subunit of NMDAR and modulates the GluN2A-associated molecular network. Moreover, we show, for the first time, that p140Cap also associates to synaptic lipid rafts and controls the selective recruitment of GluN2A and PSD95 to this specific compartment. Finally, gated-stimulated emission depletion microscopy on hippocampal neurons confirmed that p140Cap is required for embedding GluN2A clusters in lipid rafts in an activity-dependent fashion. Overall, our findings provide the molecular and functional dissection of p140Cap as a new active member of a highly dynamic synaptic network involved in memory consolidation, LTP, and LTD, which are known to be altered in neurologic and psychiatric disorders.
Collapse
Affiliation(s)
- Costanza Angelini
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, 10126, Italy
| | - Alessandro Morellato
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, 10126, Italy
| | - Annalisa Alfieri
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, 10126, Italy
| | - Lisa Pavinato
- Department of Medical Sciences, Medical Genetics Unit, University of Torino, Torino, 10126, Italy
| | - Tiziana Cravero
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, 10126, Italy
| | - Olga Teresa Bianciotto
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, 10126, Italy
| | - Vincenzo Salemme
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, 10126, Italy
| | - Dora Natalini
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, 10126, Italy
| | - Giorgia Centonze
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, 10126, Italy
| | - Alessandra Raspanti
- Neuroscience Department "Rita Levi Montalcini," University of Torino, Torino, 10125, Italy
| | - Tina Garofalo
- Department of Experimental Medicine, Sapienza University, Roma, 00161, Italy
| | - Donatella Valdembri
- Department of Oncology, University of Torino School of Medicine, Regione Gonzole, 10, 10043, Orbassano, TO, Italy
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, 10060, Italy
| | - Guido Serini
- Department of Oncology, University of Torino School of Medicine, Regione Gonzole, 10, 10043, Orbassano, TO, Italy
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, 10060, Italy
| | - Andrea Marcantoni
- Department of Drug Science, Laboratory of Cellular and Molecular Neuroscience, University of Torino, Torino, 10126, Italy
- Department of Biotechnology and Biosciences and NeuroMI, University of Milano-Bicocca, Milano, 20126, Italy
| | - Andrea Becchetti
- Department of Biotechnology and Biosciences and NeuroMI, University of Milano-Bicocca, Milano, 20126, Italy
| | - Maurizio Giustetto
- Neuroscience Department "Rita Levi Montalcini," University of Torino, Torino, 10125, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, 10126, Italy
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, 10126, Italy
| |
Collapse
|
6
|
Costamagna A, Natalini D, Camacho Leal MDP, Simoni M, Gozzelino L, Cappello P, Novelli F, Ambrogio C, Defilippi P, Turco E, Giovannetti E, Hirsch E, Cabodi S, Martini M. Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis. Gastroenterology 2022; 162:1242-1255.e11. [PMID: 34922945 DOI: 10.1053/j.gastro.2021.12.242] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 11/18/2021] [Accepted: 12/12/2021] [Indexed: 02/07/2023]
Abstract
BACKGROUND & AIMS Acinar to ductal metaplasia is the prerequisite for the initiation of Kras-driven pancreatic ductal adenocarcinoma (PDAC), and candidate genes regulating this process are emerging from genome-wide association studies. The adaptor protein p130Cas emerged as a potential PDAC susceptibility gene and a Kras-synthetic lethal interactor in pancreatic cell lines; however, its role in PDAC development has remained largely unknown. METHODS Human PDAC samples and murine KrasG12D-dependent pancreatic cancer models of increasing aggressiveness were used. p130Cas was conditionally ablated in pancreatic cancer models to investigate its role during Kras-induced tumorigenesis. RESULTS We found that high expression of p130Cas is frequently detected in PDAC and correlates with higher histologic grade and poor prognosis. In a model of Kras-driven PDAC, loss of p130Cas inhibits tumor development and potently extends median survival. Deletion of p130Cas suppresses acinar-derived tumorigenesis and progression by means of repressing PI3K-AKT signaling, even in the presence of a worsening condition like pancreatitis. CONCLUSIONS Our observations finally demonstrated that p130Cas acts downstream of Kras to boost the PI3K activity required for acinar to ductal metaplasia and subsequent tumor initiation. This demonstrates an unexpected driving role of p130Cas downstream of Kras through PI3K/AKT, thus indicating a rational therapeutic strategy of targeting the PI3K pathway in tumors with high expression of p130Cas.
Collapse
Affiliation(s)
- Andrea Costamagna
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.
| | - Dora Natalini
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy
| | - Maria Del Pilar Camacho Leal
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy
| | - Matilde Simoni
- IRCCS Ospedale San Raffaele, Preclinical Models of Cancer Unit, Milan, Italy
| | - Luca Gozzelino
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy
| | - Paola Cappello
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy; Laboratory of Tumor Immunology, Center for Experimental Research and Medical Studies, Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy
| | - Francesco Novelli
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy; Laboratory of Tumor Immunology, Center for Experimental Research and Medical Studies, Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy
| | - Chiara Ambrogio
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy
| | - Paola Defilippi
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.
| | - Emilia Turco
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.
| | - Elisa Giovannetti
- Cancer Pharmacology Laboratory, AIRC-Start-Up, Fondazione Pisana per la Scienza, San Giuliano Terme, Pisa, Italy; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands
| | - Emilio Hirsch
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy
| | - Sara Cabodi
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.
| | - Miriam Martini
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.
| |
Collapse
|
7
|
Camera M, Russo I, Zamboni V, Ammoni A, Rando S, Morellato A, Cimino I, Angelini C, Giacobini P, Oleari R, Amoruso F, Cariboni A, Franceschini I, Turco E, Defilippi P, Merlo GR. p140Cap Controls Female Fertility in Mice Acting via Glutamatergic Afference on Hypothalamic Gonadotropin-Releasing Hormone Neurons. Front Neurosci 2022; 16:744693. [PMID: 35237119 PMCID: PMC8884249 DOI: 10.3389/fnins.2022.744693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 01/20/2022] [Indexed: 11/13/2022] Open
Abstract
p140Cap, encoded by the gene SRCIN1 (SRC kinase signaling inhibitor 1), is an adaptor/scaffold protein highly expressed in the mouse brain, participating in several pre- and post-synaptic mechanisms. p140Cap knock-out (KO) female mice show severe hypofertility, delayed puberty onset, altered estrus cycle, reduced ovulation, and defective production of luteinizing hormone and estradiol during proestrus. We investigated the role of p140Cap in the development and maturation of the hypothalamic gonadotropic system. During embryonic development, migration of Gonadotropin-Releasing Hormone (GnRH) neurons from the nasal placode to the forebrain in p140Cap KO mice appeared normal, and young p140Cap KO animals showed a normal number of GnRH-immunoreactive (-ir) neurons. In contrast, adult p140Cap KO mice showed a significant loss of GnRH-ir neurons and a decreased density of GnRH-ir projections in the median eminence, accompanied by reduced levels of GnRH and LH mRNAs in the hypothalamus and pituitary gland, respectively. We examined the number of kisspeptin (KP) neurons in the rostral periventricular region of the third ventricle, the number of KP-ir fibers in the arcuate nucleus, and the number of KP-ir punctae on GnRH neurons but we found no significant changes. Consistently, the responsiveness to exogenous KP in vivo was unchanged, excluding a cell-autonomous defect on the GnRH neurons at the level of KP receptor or its signal transduction. Since glutamatergic signaling in the hypothalamus is critical for both puberty onset and modulation of GnRH secretion, we examined the density of glutamatergic synapses in p140Cap KO mice and observed a significant reduction in the density of VGLUT-ir punctae both in the preoptic area and on GnRH neurons. Our data suggest that the glutamatergic circuitry in the hypothalamus is altered in the absence of p140Cap and is required for female fertility.
Collapse
Affiliation(s)
- Mattia Camera
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Isabella Russo
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Valentina Zamboni
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Alessandra Ammoni
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Simona Rando
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Alessandro Morellato
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Irene Cimino
- Laboratory of Development and Plasticity of the Neuroendocrine Brain, Jean-Pierre Aubert Research Centre, Inserm U1172, Lille, France
- Metabolic Research Laboratories, Wellcome Trust–Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom
| | - Costanza Angelini
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Paolo Giacobini
- Laboratory of Development and Plasticity of the Neuroendocrine Brain, Jean-Pierre Aubert Research Centre, Inserm U1172, Lille, France
| | - Roberto Oleari
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
| | - Federica Amoruso
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
| | - Anna Cariboni
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
| | - Isabelle Franceschini
- Physiologie de la Reproduction et des Comportements, French National Centre for Scientific Research, French Institute of the Horse and Riding, French National Research Institute for Agriculture, Food and Environment, Université de Tours, Nouzilly, France
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- *Correspondence: Paola Defilippi,
| | - Giorgio R. Merlo
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Giorgio R. Merlo,
| |
Collapse
|
8
|
Fernandez L, Blanco-Rey M, Castrillo-Bodero R, Ilyn M, Ali K, Turco E, Corso M, Ormaza M, Gargiani P, Valbuena MA, Mugarza A, Moras P, Sheverdyaeva PM, Kundu AK, Jugovac M, Laubschat C, Ortega JE, Schiller F. Correction: Influence of 4f filling on electronic and magnetic properties of rare earth-Au surface compounds. Nanoscale 2021; 13:20704. [PMID: 34874396 DOI: 10.1039/d1nr90260a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Correction for 'Influence of 4f filling on electronic and magnetic properties of rare earth-Au surface compounds' by L. Fernandez et al., Nanoscale, 2020, 12, 22258-22267, DOI: 10.1039/D0NR04964F.
Collapse
Affiliation(s)
- L Fernandez
- Universidad del País Vasco UPV-EHU, Dpto. Física Aplicada I, 20018 San Sebastián, Spain
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - M Blanco-Rey
- Universidad del País Vasco UPV-EHU, Dpto. de Polímeros y Materiales Avanzados: Física, Química y Tecnología, 20018 San Sebastián, Spain
- Donostia International Physics Center, 20018 Donostia-San Sebastián, Spain.
| | - R Castrillo-Bodero
- Donostia International Physics Center, 20018 Donostia-San Sebastián, Spain.
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - M Ilyn
- Donostia International Physics Center, 20018 Donostia-San Sebastián, Spain.
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - K Ali
- Donostia International Physics Center, 20018 Donostia-San Sebastián, Spain.
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - E Turco
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - M Corso
- Donostia International Physics Center, 20018 Donostia-San Sebastián, Spain.
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - M Ormaza
- Universidad del País Vasco UPV-EHU, Dpto. Física Aplicada I, 20018 San Sebastián, Spain
| | - P Gargiani
- ALBA Synchrotron Light Source, Carretera BP 1413 km 3.3, 08290 Cerdanyola del Vallès, Spain
| | - M A Valbuena
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, 08193 Barcelona, Spain
- IMDEA Nanociencia, 28049 Madrid, Spain
| | - A Mugarza
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, 08193 Barcelona, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), 08070 Barcelona, Spain
| | - P Moras
- Istituto di Struttura della Materia, Consiglio Nazionale delle Ricerche, 34149 Trieste, Italy
| | - P M Sheverdyaeva
- Istituto di Struttura della Materia, Consiglio Nazionale delle Ricerche, 34149 Trieste, Italy
| | - Asish K Kundu
- Istituto di Struttura della Materia, Consiglio Nazionale delle Ricerche, 34149 Trieste, Italy
| | - M Jugovac
- Istituto di Struttura della Materia, Consiglio Nazionale delle Ricerche, 34149 Trieste, Italy
| | - C Laubschat
- Institut für Festkörper- und Materialphysik, Technische Universität Dresden, 01062 Dresden, Germany
| | - J E Ortega
- Universidad del País Vasco UPV-EHU, Dpto. Física Aplicada I, 20018 San Sebastián, Spain
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - F Schiller
- Donostia International Physics Center, 20018 Donostia-San Sebastián, Spain.
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| |
Collapse
|
9
|
Seclì L, Avalle L, Poggio P, Fragale G, Cannata C, Conti L, Iannucci A, Carrà G, Rubinetto C, Miniscalco B, Hirsch E, Poli V, Morotti A, De Andrea M, Turco E, Cavallo F, Fusella F, Brancaccio M. Targeting the extracellular HSP90 co-chaperone Morgana inhibits cancer cell migration and promotes anti-cancer immunity. Cancer Res 2021; 81:4794-4807. [PMID: 34193441 DOI: 10.1158/0008-5472.can-20-3150] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Revised: 05/18/2021] [Accepted: 06/28/2021] [Indexed: 11/16/2022]
Abstract
Heat shock protein 90 (HSP90) is secreted by cancer cells into the extracellular milieu, where it exerts pro-tumoral activities by activating extracellular substrate proteins and triggering autocrine signals through cancer cell surface receptors. Emerging evidence indicates that HSP90 co-chaperones are also secreted and may direct HSP90 extracellular activities. In this study, we found that the HSP90 co-chaperone Morgana is released by cancer cells and, in association with HSP90, induces cancer cell migration through TLR2, TLR4, and LRP1. In syngeneic cancer mouse models, a monoclonal antibody targeting Morgana extracellular activity reduced primary tumor growth via macrophage-dependent recruitment of CD8+ T lymphocytes, blocked cancer cell migration, and inhibited metastatic spreading. Overall, this data defines Morgana as a new player in the HSP90 extracellular interactome and suggests that Morgana may regulate HSP90 activity to promote cancer cell migration and suppress anti-tumor immunity.
Collapse
Affiliation(s)
- Laura Seclì
- Molecular Biotechnology and Health Sciences, University of Turin
| | - Lidia Avalle
- Molecular Biotechnology and Health Sciences, University of Turin
| | - Pietro Poggio
- Molecular Biotechnology and Health Sciences, University of Turin
| | - Giuseppe Fragale
- Molecular Biotechnology and Health Sciences, University of Turin
| | | | - Laura Conti
- Department of Molecular Biotechnology and Health Sciences - Molecular Biotechnology Center, University of Turin
| | - Andrea Iannucci
- CAAD-Center for Translational Research on Autoimmune and Allergic Diseases, University of Eastern Piedmont
| | - Giovanna Carrà
- Department of Clinical and Biological Sciences, University of Turin
| | | | | | - Emilio Hirsch
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin
| | - Valeria Poli
- Department of Molecular Biotechnology and Health Sciences, University of Turin
| | | | - Marco De Andrea
- Public Health and Pediatric Sciences, University of Turin, Medical School
| | - Emilia Turco
- Molecular Biotechnology and Health Sciences, University of Torino, Molecular Biotechnology Center
| | - Federica Cavallo
- Department of Molecular Biotechnology and Health Sciences, University of Turin
| | - Federica Fusella
- Molecular Biotechnology and Health Sciences, University of Turin
| | - Mara Brancaccio
- Molecular Biotechnology and Health Sciences, University of Turin
| |
Collapse
|
10
|
Peikert K, Federti E, Matte A, Constantin G, Pietronigro EC, Fabene PF, Defilippi P, Turco E, Del Gallo F, Pucci P, Amoresano A, Illiano A, Cozzolino F, Monti M, Garello F, Terreno E, Alper SL, Glaß H, Pelzl L, Akgün K, Ziemssen T, Ordemann R, Lang F, Brunati AM, Tibaldi E, Andolfo I, Iolascon A, Bertini G, Buffelli M, Zancanaro C, Lorenzetto E, Siciliano A, Bonifacio M, Danek A, Walker RH, Hermann A, De Franceschi L. Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis. Acta Neuropathol Commun 2021; 9:81. [PMID: 33941276 PMCID: PMC8091687 DOI: 10.1186/s40478-021-01181-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2021] [Accepted: 04/14/2021] [Indexed: 11/18/2022] Open
Abstract
Chorea-Acanthocytosis (ChAc) is a devastating, little understood, and currently untreatable neurodegenerative disease caused by VPS13A mutations. Based on our recent demonstration that accumulation of activated Lyn tyrosine kinase is a key pathophysiological event in human ChAc cells, we took advantage of Vps13a−/− mice, which phenocopied human ChAc. Using proteomic approach, we found accumulation of active Lyn, γ-synuclein and phospho-tau proteins in Vps13a−/− basal ganglia secondary to impaired autophagy leading to neuroinflammation. Mice double knockout Vps13a−/− Lyn−/− showed normalization of red cell morphology and improvement of autophagy in basal ganglia. We then in vivo tested pharmacologic inhibitors of Lyn: dasatinib and nilotinib. Dasatinib failed to cross the mouse brain blood barrier (BBB), but the more specific Lyn kinase inhibitor nilotinib, crosses the BBB. Nilotinib ameliorates both Vps13a−/− hematological and neurological phenotypes, improving autophagy and preventing neuroinflammation. Our data support the proposal to repurpose nilotinib as new therapeutic option for ChAc patients.
Collapse
|
11
|
Enrico Bena C, Del Giudice M, Grob A, Gueudré T, Miotto M, Gialama D, Osella M, Turco E, Ceroni F, De Martino A, Bosia C. Initial cell density encodes proliferative potential in cancer cell populations. Sci Rep 2021; 11:6101. [PMID: 33731745 PMCID: PMC7969775 DOI: 10.1038/s41598-021-85406-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 02/26/2021] [Indexed: 01/18/2023] Open
Abstract
Individual cells exhibit specific proliferative responses to changes in microenvironmental conditions. Whether such potential is constrained by the cell density throughout the growth process is however unclear. Here, we identify a theoretical framework that captures how the information encoded in the initial density of cancer cell populations impacts their growth profile. By following the growth of hundreds of populations of cancer cells, we found that the time they need to adapt to the environment decreases as the initial cell density increases. Moreover, the population growth rate shows a maximum at intermediate initial densities. With the support of a mathematical model, we show that the observed interdependence of adaptation time and growth rate is significantly at odds both with standard logistic growth models and with the Monod-like function that governs the dependence of the growth rate on nutrient levels. Our results (i) uncover and quantify a previously unnoticed heterogeneity in the growth dynamics of cancer cell populations; (ii) unveil how population growth may be affected by single-cell adaptation times; (iii) contribute to our understanding of the clinically-observed dependence of the primary and metastatic tumor take rates on the initial density of implanted cancer cells.
Collapse
Affiliation(s)
- Chiara Enrico Bena
- CNRS, Institut de Biologie Paris-Seine (IBPS), Laboratoire Jean Perrin (LJP), Sorbonne Université, 75005, Paris, France.,IIGM - Italian Institute for Genomic Medicine, c/o IRCCS, Str. Prov.le 142, km 3.95, 10060, Candiolo, Italy
| | - Marco Del Giudice
- IIGM - Italian Institute for Genomic Medicine, c/o IRCCS, Str. Prov.le 142, km 3.95, 10060, Candiolo, Italy.,Candiolo Cancer Institute, FPO - IRCCS, Str. Prov.le 142, km 3.95, 10060, Candiolo, Italy
| | - Alice Grob
- Department of Life Sciences, Imperial College London, London, UK.,Imperial College Centre for Synthetic Biology, London, UK
| | - Thomas Gueudré
- IIGM - Italian Institute for Genomic Medicine, c/o IRCCS, Str. Prov.le 142, km 3.95, 10060, Candiolo, Italy
| | - Mattia Miotto
- Department of Physics, Sapienza University, Piazzale Aldo Moro 5, 00185, Rome, Italy
| | - Dimitra Gialama
- Department of Chemical Engineering, Imperial College London, London, UK
| | - Matteo Osella
- Physics Department and INFN, University of Turin, Via P. Giuria 1, 10125, Turin, Italy
| | - Emilia Turco
- Molecular Biotechnology Center, University of Turin, Via Nizza 52, 10126, Turin, Italy
| | - Francesca Ceroni
- Department of Chemical Engineering, Imperial College London, London, UK.,Imperial College Centre for Synthetic Biology, London, UK
| | - Andrea De Martino
- IIGM - Italian Institute for Genomic Medicine, c/o IRCCS, Str. Prov.le 142, km 3.95, 10060, Candiolo, Italy.,Soft and Living Matter Lab, CNR-NANOTEC, Rome, Italy
| | - Carla Bosia
- IIGM - Italian Institute for Genomic Medicine, c/o IRCCS, Str. Prov.le 142, km 3.95, 10060, Candiolo, Italy. .,Department of Applied Science and Technology, Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129, Turin, Italy.
| |
Collapse
|
12
|
Chapelle J, Baudino A, Torelli F, Savino A, Morellato A, Angelini C, Salemme V, Centonze G, Natalini D, Gai M, Poli V, Kähne T, Turco E, Defilippi P. The N-terminal domain of the adaptor protein p140Cap interacts with Tiam1 and controls Tiam1/Rac1 axis. Am J Cancer Res 2020; 10:4308-4324. [PMID: 33415001 PMCID: PMC7783762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 07/09/2020] [Indexed: 06/12/2023] Open
Abstract
The p140Cap adaptor protein, encoded by the SRCIN1 gene, negatively controls tumor progression, as demonstrated in the subgroup of HER2-amplified breast cancers and in neuroblastoma patients, where high p140Cap expression predicts a decreased probability of developing metastasis, with a significantly prolonged survival. In NeuT mice, a preclinical model or Her2-positive breast cancer, we previously reported that p140Cap counteracts Her2-dependent breast cancer progression, associating with the specific Rac1 Guanine Nucleotide Exchange Factor, Tiam1, and limiting the activation of both Tiam1 and Rac1. Here, we show that in TUBO breast cancer cells derived from the NeuT tumors, p140Cap expression causes Tiam1 redistribution along the apicobasal junctional axis. Furthermore, p140Cap and Tiam1 interact with E-cadherin, a member of the adherence junction, with a concomitant increase of E-cadherin at the cell membrane. We characterized biochemically the interaction between p140Cap and Tiam1, showing that the amino terminal region of p140Cap (1-287 amino acids) is sufficient to associate with full length Tiam1, and with the truncated catalytic domain of Tiam1, with a concomitant decrease of the Tiam1 activity. Moreover, in a large cohort of Her2 positive breast cancer, high levels of SRCIN1 expression positively correlates with increased survival in patients with high TIAM1 expression. Overall, our findings sustain a protective role of p140Cap in Her2 positive breast cancer, where p140Cap can associate with Tiam1 and negatively regulate the Tiam1/Rac1 axis.
Collapse
Affiliation(s)
- Jennifer Chapelle
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| | - Annalisa Baudino
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| | - Federico Torelli
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| | - Aurora Savino
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| | - Alessandro Morellato
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| | - Costanza Angelini
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| | - Vincenzo Salemme
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| | - Giorgia Centonze
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| | - Dora Natalini
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| | - Marta Gai
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| | - Valeria Poli
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| | - Thilo Kähne
- Institute of Experimental Internal Medicine, Medical Faculty, Otto von Guericke UniversityMagdeburg 39120, Germany
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of TorinoTorino 10126, Italy
| |
Collapse
|
13
|
Fernandez L, Blanco-Rey M, Castrillo-Bodero R, Ilyn M, Ali K, Turco E, Corso M, Ormaza M, Gargiani P, Valbuena MA, Mugarza A, Moras P, Sheverdyaeva PM, Kundu AK, Jugovac M, Laubschat C, Ortega JE, Schiller F. Influence of 4f filling on electronic and magnetic properties of rare earth-Au surface compounds. Nanoscale 2020; 12:22258-22267. [PMID: 33146198 DOI: 10.1039/d0nr04964f] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
One-atom-thick rare-earth/noble metal (RE-NM) compounds are attractive materials to investigate two-dimensional magnetism, since they are easy to synthesize into a common RE-NM2 structure with high crystal perfection. Here we perform a comparative study of the GdAu2, HoAu2, and YbAu2 monolayer compounds grown on Au(111). We find the same atomic lattice quality and moiré superlattice periodicity in the three cases, but different electronic properties and magnetism. The YbAu2 monolayer reveals the characteristic electronic signatures of a mixed-valence configuration in the Yb atom. In contrast, GdAu2 and HoAu2 show the trivalent character of the rare-earth and ferromagnetic transitions below 22 K. Yet, the GdAu2 monolayer has an in-plane magnetic easy-axis, versus the out-of-plane one in HoAu2. The electronic bands of the two trivalent compounds are very similar, while the divalent YbAu2 monolayer exhibits different band features. In the latter, a strong 4f-5d hybridization is manifested in neatly resolved avoided crossings near the Fermi level. First principles theory points to a residual presence of empty 4f states, explaining the fluctuating valence of Yb in the YbAu2 monolayer.
Collapse
Affiliation(s)
- L Fernandez
- Universidad del País Vasco UPV-EHU, Dpto. Física Aplicada I, 20018 San Sebastián, Spain
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - M Blanco-Rey
- Universidad del País Vasco UPV-EHU, Dpto. de Polímeros y Materiales Avanzados: Física, Química y Tecnología, 20018 San Sebastián, Spain
- Donostia International Physics Center, 20018 Donostia-San Sebastián, Spain.
| | - R Castrillo-Bodero
- Donostia International Physics Center, 20018 Donostia-San Sebastián, Spain.
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - M Ilyn
- Donostia International Physics Center, 20018 Donostia-San Sebastián, Spain.
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - K Ali
- Donostia International Physics Center, 20018 Donostia-San Sebastián, Spain.
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - E Turco
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - M Corso
- Donostia International Physics Center, 20018 Donostia-San Sebastián, Spain.
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - M Ormaza
- Universidad del País Vasco UPV-EHU, Dpto. Física Aplicada I, 20018 San Sebastián, Spain
| | - P Gargiani
- ALBA Synchrotron Light Source, Carretera BP 1413 km 3.3, 08290 Cerdanyola del Vallès, Spain
| | - M A Valbuena
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, 08193 Barcelona, Spain
- IMDEA Nanociencia, 28049 Madrid, Spain
| | - A Mugarza
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, 08193 Barcelona, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), 08070 Barcelona, Spain
| | - P Moras
- Istituto di Struttura della Materia, Consiglio Nazionale delle Ricerche, 34149 Trieste, Italy
| | - P M Sheverdyaeva
- Istituto di Struttura della Materia, Consiglio Nazionale delle Ricerche, 34149 Trieste, Italy
| | - Asish K Kundu
- Istituto di Struttura della Materia, Consiglio Nazionale delle Ricerche, 34149 Trieste, Italy
| | - M Jugovac
- Istituto di Struttura della Materia, Consiglio Nazionale delle Ricerche, 34149 Trieste, Italy
| | - C Laubschat
- Institut für Festkörper- und Materialphysik, Technische Universität Dresden, 01062 Dresden, Germany
| | - J E Ortega
- Universidad del País Vasco UPV-EHU, Dpto. Física Aplicada I, 20018 San Sebastián, Spain
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| | - F Schiller
- Donostia International Physics Center, 20018 Donostia-San Sebastián, Spain.
- Centro de Física de Materiales CSIC/UPV-EHU-Materials Physics Center, 20018 San Sebastián, Spain
| |
Collapse
|
14
|
Salemme V, Angelini C, Chapelle J, Centonze G, Natalini D, Morellato A, Taverna D, Turco E, Ala U, Defilippi P. The p140Cap adaptor protein as a molecular hub to block cancer aggressiveness. Cell Mol Life Sci 2020; 78:1355-1367. [PMID: 33079227 PMCID: PMC7904710 DOI: 10.1007/s00018-020-03666-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Revised: 09/03/2020] [Accepted: 10/05/2020] [Indexed: 01/03/2023]
Abstract
The p140Cap adaptor protein is a scaffold molecule encoded by the SRCIN1 gene, which is physiologically expressed in several epithelial tissues and in the neurons. However, p140Cap is also strongly expressed in a significant subset of cancers including breast cancer and neuroblastoma. Notably, cancer patients with high p140Cap expression in their primary tumors have a lower probability of developing a distant event and ERBB2-positive breast cancer sufferers show better survival. In neuroblastoma patients, SRCIN1 mRNA levels represent an independent risk factor, which is inversely correlated to disease aggressiveness. Consistent with clinical data, SRCIN1 gain or loss of function mouse models demonstrated that p140Cap may affect tumor growth and metastasis formation by controlling the signaling pathways involved in tumorigenesis and metastatic features. This study reviews data showing the relevance of SRCIN1/p140Cap in cancer patients, the impact of SRCIN1 status on p140Cap expression, the specific mechanisms through which p140Cap can limit cancer progression, the molecular functions regulated by p140Cap, along with the p140Cap interactome, to unveil its key role for patient stratification in clinics.
Collapse
Affiliation(s)
- Vincenzo Salemme
- Department of Molecular Biotechnology and Health Science, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy
| | - Costanza Angelini
- Department of Molecular Biotechnology and Health Science, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy
| | - Jennifer Chapelle
- Department of Molecular Biotechnology and Health Science, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy
| | - Giorgia Centonze
- Department of Molecular Biotechnology and Health Science, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy
| | - Dora Natalini
- Department of Molecular Biotechnology and Health Science, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy
| | - Alessandro Morellato
- Department of Molecular Biotechnology and Health Science, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy
| | - Daniela Taverna
- Department of Molecular Biotechnology and Health Science, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Science, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy
| | - Ugo Ala
- Department of Veterinary Sciences, Università degli Studi di Torino, Largo Paolo Braccini 2, 10095, Grugliasco, TO, Italy.
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Science, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy.
| |
Collapse
|
15
|
Vitadello M, Sorge M, Percivalle E, Germinario E, Danieli-Betto D, Turco E, Tarone G, Brancaccio M, Gorza L. Loss of melusin is a novel, neuronal NO synthase/FoxO3-independent master switch of unloading-induced muscle atrophy. J Cachexia Sarcopenia Muscle 2020; 11:802-819. [PMID: 32154658 PMCID: PMC7296270 DOI: 10.1002/jcsm.12546] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2019] [Revised: 12/04/2019] [Accepted: 12/19/2019] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Unloading/disuse induces skeletal muscle atrophy in bedridden patients and aged people, who cannot prevent it by means of exercise. Because interventions against known atrophy initiators, such as oxidative stress and neuronal NO synthase (nNOS) redistribution, are only partially effective, we investigated the involvement of melusin, a muscle-specific integrin-associated protein and a recognized regulator of protein kinases and mechanotransduction in cardiomyocytes. METHODS Muscle atrophy was induced in the rat soleus by tail suspension and in the human vastus lateralis by bed rest. Melusin expression was investigated at the protein and transcript level and after treatment of tail-suspended rats with atrophy initiator inhibitors. Myofiber size, sarcolemmal nNOS activity, FoxO3 myonuclear localization, and myofiber carbonylation of the unloaded rat soleus were studied after in vivo melusin replacement by cDNA electroporation, and muscle force, myofiber size, and atrogene expression after adeno-associated virus infection. In vivo interference of exogenous melusin with dominant-negative kinases and other atrophy attenuators (Grp94 cDNA; 7-nitroindazole) on size of unloaded rat myofibers was also explored. RESULTS Unloading/disuse reduced muscle melusin protein levels to about 50%, already after 6 h in the tail-suspended rat (P < 0.001), and to about 35% after 8 day bed rest in humans (P < 0.05). In the unloaded rat, melusin loss occurred despite of the maintenance of β1D integrin levels and was not abolished by treatments inhibiting mitochondrial oxidative stress, or nNOS activity and redistribution. Expression of exogenous melusin by cDNA transfection attenuated atrophy of 7 day unloaded rat myofibers (-31%), compared with controls (-48%, P = 0.001), without hampering the decrease in sarcolemmal nNOS activity and the increase in myonuclear FoxO3 and carbonylated myofibers. Infection with melusin-expressing adeno-associated virus ameliorated contractile properties of 7 day unloaded muscles (P ≤ 0.05) and relieved myofiber atrophy (-33%) by reducing Atrogin-1 and MurF-1 transcripts (P ≤ 0.002), despite of a two-fold increase in FoxO3 protein levels (P = 0.03). Atrophy attenuation by exogenous melusin did not result from rescue of Akt, ERK, or focal adhesion kinase activity, because it persisted after co-transfection with dominant-negative kinase forms (P < 0.01). Conversely, melusin cDNA transfection, combined with 7-nitroindazole treatment or with cDNA transfection of the nNOS-interacting chaperone Grp94, abolished 7 day unloaded myofiber atrophy. CONCLUSIONS Disuse/unloading-induced loss of melusin is an early event in muscle atrophy which occurs independently from mitochondrial oxidative stress, nNOS redistribution, and FoxO3 activation. Only preservation of melusin levels and sarcolemmal nNOS localization fully prevented muscle mass loss, demonstrating that both of them act as independent, but complementary, master switches of muscle disuse atrophy.
Collapse
Affiliation(s)
- Maurizio Vitadello
- Department of Biomedical Sciences, University of Padova, Padova, Italy.,CNR-Institute for Neuroscience, Padova Section, Padova, Italy
| | - Matteo Sorge
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Elena Percivalle
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Elena Germinario
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| | | | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Guido Tarone
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Mara Brancaccio
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Luisa Gorza
- Department of Biomedical Sciences, University of Padova, Padova, Italy
| |
Collapse
|
16
|
Porta C, Consonni FM, Morlacchi S, Sangaletti S, Bleve A, Totaro MG, Larghi P, Rimoldi M, Tripodo C, Strauss L, Banfi S, Storto M, Pressiani T, Rimassa L, Tartari S, Ippolito A, Doni A, Soldà G, Duga S, Piccolo V, Ostuni R, Natoli G, Bronte V, Balzac F, Turco E, Hirsch E, Colombo MP, Sica A. Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs. Cancer Res 2020; 80:2874-2888. [PMID: 32265223 DOI: 10.1158/0008-5472.can-19-2843] [Citation(s) in RCA: 75] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Revised: 02/28/2020] [Accepted: 04/02/2020] [Indexed: 11/16/2022]
Abstract
Myeloid-derived suppressor cells (MDSC) include immature monocytic (M-MDSC) and granulocytic (PMN-MDSC) cells that share the ability to suppress adaptive immunity and to hinder the effectiveness of anticancer treatments. Of note, in response to IFNγ, M-MDSCs release the tumor-promoting and immunosuppressive molecule nitric oxide (NO), whereas macrophages largely express antitumor properties. Investigating these opposing activities, we found that tumor-derived prostaglandin E2 (PGE2) induces nuclear accumulation of p50 NF-κB in M-MDSCs, diverting their response to IFNγ toward NO-mediated immunosuppression and reducing TNFα expression. At the genome level, p50 NF-κB promoted binding of STAT1 to regulatory regions of selected IFNγ-dependent genes, including inducible nitric oxide synthase (Nos2). In agreement, ablation of p50 as well as pharmacologic inhibition of either the PGE2 receptor EP2 or NO production reprogrammed M-MDSCs toward a NOS2low/TNFαhigh phenotype, restoring the in vivo antitumor activity of IFNγ. Our results indicate that inhibition of the PGE2/p50/NO axis prevents MDSC-suppressive functions and restores the efficacy of anticancer immunotherapy. SIGNIFICANCE: Tumor-derived PGE2-mediated induction of nuclear p50 NF-κB epigenetically reprograms the response of monocytic cells to IFNγ toward an immunosuppressive phenotype, thus retrieving the anticancer properties of IFNγ. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/13/2874/F1.large.jpg.
Collapse
Affiliation(s)
- Chiara Porta
- Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy.,Center for Translational Research on Autoimmune & Allergic Diseases (CAAD) Cso Trieste 15/A, Novara, Italy
| | | | - Sara Morlacchi
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
| | | | - Augusto Bleve
- Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy
| | | | - Paola Larghi
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
| | - Monica Rimoldi
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
| | - Claudio Tripodo
- Human Pathology Section, Department of Health Sciences, University of Palermo, Palermo, Italy
| | - Laura Strauss
- Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy
| | - Stefania Banfi
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
| | - Mariangela Storto
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
| | - Tiziana Pressiani
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
| | - Lorenza Rimassa
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
| | - Silvia Tartari
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
| | - Alessandro Ippolito
- Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy
| | - Andrea Doni
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
| | - Giulia Soldà
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.,Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
| | - Stefano Duga
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.,Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
| | - Viviana Piccolo
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
| | - Renato Ostuni
- San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.,Vita-Salute San Raffaele University, Milan, Italy
| | - Gioacchino Natoli
- Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.,Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
| | - Vincenzo Bronte
- Department of Medicine, Verona University Hospital, Verona, Italy
| | - Fiorella Balzac
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy
| | - Emilio Hirsch
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy
| | - Mario P Colombo
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Antonio Sica
- Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy. .,Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy
| |
Collapse
|
17
|
Russo I, Gavello D, Menna E, Vandael D, Veglia C, Morello N, Corradini I, Focchi E, Alfieri A, Angelini C, Bianchi FT, Morellato A, Marcantoni A, Sassoè-Pognetto M, Ottaviani MM, Yekhlef L, Giustetto M, Taverna S, Carabelli V, Matteoli M, Carbone E, Turco E, Defilippi P. p140Cap Regulates GABAergic Synaptogenesis and Development of Hippocampal Inhibitory Circuits. Cereb Cortex 2020; 29:91-105. [PMID: 29161354 DOI: 10.1093/cercor/bhx306] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Accepted: 10/23/2017] [Indexed: 01/19/2023] Open
Abstract
The neuronal scaffold protein p140Cap was investigated during hippocampal network formation. p140Cap is present in presynaptic GABAergic terminals and its genetic depletion results in a marked alteration of inhibitory synaptic activity. p140Cap-/- cultured neurons display higher frequency of miniature inhibitory postsynaptic currents (mIPSCs) with no changes of their mean amplitude. Consistent with a potential presynaptic alteration of basal GABA release, p140Cap-/- neurons exhibit a larger synaptic vesicle readily releasable pool, without any variation of single GABAA receptor unitary currents and number of postsynaptic channels. Furthermore, p140Cap-/- neurons show a premature and enhanced network synchronization and appear more susceptible to 4-aminopyridine-induced seizures in vitro and to kainate-induced seizures in vivo. The hippocampus of p140Cap-/- mice showed a significant increase in the number of both inhibitory synapses and of parvalbumin- and somatostatin-expressing interneurons. Specific deletion of p140Cap in forebrain interneurons resulted in increased susceptibility to in vitro epileptic events and increased inhibitory synaptogenesis, comparable to those observed in p140Cap-/- mice. Altogether, our data demonstrate that p140Cap finely tunes inhibitory synaptogenesis and GABAergic neurotransmission, thus regulating the establishment and maintenance of the proper hippocampal excitatory/inhibitory balance.
Collapse
Affiliation(s)
- Isabella Russo
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Daniela Gavello
- Department of Drug Science, University of Torino, Torino, Italy.,NIS Centre of Excellence, Torino, Italy
| | - Elisabetta Menna
- Institute of Neuroscience, CNR, Milano, Italy.,Istituto Clinico Humanitas, IRCCS, Rozzano, Italy
| | - David Vandael
- Department of Drug Science, University of Torino, Torino, Italy.,NIS Centre of Excellence, Torino, Italy
| | - Carola Veglia
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Noemi Morello
- Department of Neuroscience, University of Torino, Torino, Italy
| | - Irene Corradini
- Institute of Neuroscience, CNR, Milano, Italy.,Istituto Clinico Humanitas, IRCCS, Rozzano, Italy
| | | | - Annalisa Alfieri
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Costanza Angelini
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Federico Tommaso Bianchi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.,Neuroscience Institute Cavalieri Ottolenghi, University of Torino, Orbassano, Italy
| | - Alessandro Morellato
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Andrea Marcantoni
- Department of Drug Science, University of Torino, Torino, Italy.,NIS Centre of Excellence, Torino, Italy
| | - Marco Sassoè-Pognetto
- Department of Neuroscience, University of Torino, Torino, Italy.,National Institute of Neuroscience-Italy, Torino, Italy
| | | | - Latefa Yekhlef
- Division of Neuroscience, San Raffaele Scientific Institute, Milano, Italy
| | - Maurizio Giustetto
- Department of Neuroscience, University of Torino, Torino, Italy.,National Institute of Neuroscience-Italy, Torino, Italy
| | - Stefano Taverna
- Division of Neuroscience, San Raffaele Scientific Institute, Milano, Italy
| | - Valentina Carabelli
- Department of Drug Science, University of Torino, Torino, Italy.,NIS Centre of Excellence, Torino, Italy
| | - Michela Matteoli
- Institute of Neuroscience, CNR, Milano, Italy.,Istituto Clinico Humanitas, IRCCS, Rozzano, Italy
| | - Emilio Carbone
- Department of Drug Science, University of Torino, Torino, Italy.,NIS Centre of Excellence, Torino, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| |
Collapse
|
18
|
Costamagna A, Rossi Sebastiano M, Natalini D, Simoni M, Valabrega G, Defilippi P, Visentin S, Ermondi G, Turco E, Caron G, Cabodi S. Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents. Sci Rep 2019; 9:17729. [PMID: 31758081 PMCID: PMC6874561 DOI: 10.1038/s41598-019-54252-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Chapelle J, Sorokina O, McLean C, Salemme V, Alfieri A, Angelini C, Morellato A, Adrait A, Menna E, Matteoli M, Couté Y, Ala U, Turco E, Defilippi P, Armstrong JD. Dissecting the Shared and Context-Dependent Pathways Mediated by the p140Cap Adaptor Protein in Cancer and in Neurons. Front Cell Dev Biol 2019; 7:222. [PMID: 31681758 PMCID: PMC6803390 DOI: 10.3389/fcell.2019.00222] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Accepted: 09/19/2019] [Indexed: 12/26/2022] Open
Abstract
The p140Cap adaptor protein is a scaffold molecule physiologically expressed in few epithelial tissues, such as the mammary gland, and in differentiated neurons. While the role of p140Cap in mammary gland epithelia is not still understood, we already know that a significant subset of breast cancers express p140Cap. In the subgroup of ERBB2-amplified breast cancers, a high p140Cap status predicts a significantly lower probability of developing a distant event and a clear difference in survival. p140Cap is causal in dampening ERBB2-positive tumor cell progression, impairing tumor onset and growth, and counteracting epithelial mesenchymal transition, resulting in decreased metastasis formation. Since only a few p140Cap interacting proteins have been identified in breast cancer and the molecular complexes and pathways underlying the cancer function of p140Cap are largely unknown, we generated a p140Cap interactome from ERBB2-positive breast cancer cells, identifying cancer specific components and those shared with the synaptic interactome. We identified 373 interacting proteins in cancer cells, including those with functions relevant to cell adhesion, protein homeostasis, regulation of cell cycle and apoptosis, which are frequently deregulated in cancer. Within the interactome, we identified 15 communities (clusters) with topology-functional relationships. In neurons, where p140Cap is key in regulating synaptogenesis, synaptic transmission and synaptic plasticity, it establishes an extensive interactome with proteins that cluster to sub complexes located in the postsynaptic density. p140Cap interactors converge on key synaptic processes, including synaptic transmission, actin cytoskeleton remodeling and cell-cell junction organization. Comparing the breast cancer to the synaptic interactome, we found 39 overlapping proteins, a relatively small overlap. However, cell adhesion and remodeling of actin cytoskeleton clearly emerge as common terms in the shared subset. Thus, the functional signature of the two interactomes is primarily determined by organ/tissue and functional specificity, while the overlap provides a list of shared functional terms, which might be linked to both cancer and neurological functions.
Collapse
Affiliation(s)
- Jennifer Chapelle
- Department of Molecular Biotechnology and Health Sciences, Università degli Studi di Torino, Turin, Italy
| | - Oksana Sorokina
- Simons Initiative for the Developing Brain, School of Informatics, The University of Edinburgh, Edinburgh, United Kingdom
| | - Colin McLean
- Simons Initiative for the Developing Brain, School of Informatics, The University of Edinburgh, Edinburgh, United Kingdom
| | - Vincenzo Salemme
- Department of Molecular Biotechnology and Health Sciences, Università degli Studi di Torino, Turin, Italy
| | - Annalisa Alfieri
- Department of Molecular Biotechnology and Health Sciences, Università degli Studi di Torino, Turin, Italy
| | - Costanza Angelini
- Department of Molecular Biotechnology and Health Sciences, Università degli Studi di Torino, Turin, Italy
| | - Alessandro Morellato
- Department of Molecular Biotechnology and Health Sciences, Università degli Studi di Torino, Turin, Italy
| | - Annie Adrait
- Univ. Grenoble Alpes, CEA, INSERM, IRIG, BGE, Grenoble, France
| | - Elisabetta Menna
- Institute of Neuroscience, CNR, Milan, Italy
- Istituto Clinico Humanitas, IRCCS, Rozzano, Italy
| | - Michela Matteoli
- Institute of Neuroscience, CNR, Milan, Italy
- Istituto Clinico Humanitas, IRCCS, Rozzano, Italy
| | - Yohann Couté
- Univ. Grenoble Alpes, CEA, INSERM, IRIG, BGE, Grenoble, France
| | - Ugo Ala
- Department of Veterinary Sciences, Università degli Studi di Torino, Turin, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, Università degli Studi di Torino, Turin, Italy
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, Università degli Studi di Torino, Turin, Italy
| | - J. Douglas Armstrong
- Simons Initiative for the Developing Brain, School of Informatics, The University of Edinburgh, Edinburgh, United Kingdom
| |
Collapse
|
20
|
Grasso S, Cangelosi D, Chapelle J, Alzona M, Centonze G, Lamolinara A, Salemme V, Angelini C, Morellato A, Saglietto A, Bianchi FT, Cabodi S, Salaroglio IC, Fusella F, Ognibene M, Iezzi M, Pezzolo A, Poli V, Di Cunto F, Eva A, Riganti C, Varesio L, Turco E, Defilippi P. Correction to: The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma. Cell Death Differ 2019; 27:1448. [PMID: 31488891 DOI: 10.1038/s41418-019-0405-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Collapse
Affiliation(s)
- Silvia Grasso
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Davide Cangelosi
- Laboratory of Molecular Biology, Giannina Gaslini Institute, 16147, Genova, Italy
| | - Jennifer Chapelle
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Melissa Alzona
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Giorgia Centonze
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Alessia Lamolinara
- Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, Italy
| | - Vincenzo Salemme
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Costanza Angelini
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Alessandro Morellato
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Andrea Saglietto
- Cardiology Division, Department of Medical Sciences, University of Torino, 10126, Torino, Italy
| | - Federico Tommaso Bianchi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy.,Neuroscience Institute Cavalieri Ottolenghi, Regione Gonzole 10, 10043, Orbassano (TO), Italy
| | - Sara Cabodi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Iris Chiara Salaroglio
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy.,Department of Oncology, University of Torino, 10126, Torino, Italy
| | - Federica Fusella
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Marzia Ognibene
- Laboratorio Cellule Staminali Post Natali e Terapie Cellulari, Istituto Giannina Gaslini, Genova, Italy
| | - Manuela Iezzi
- Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, Italy
| | - Annalisa Pezzolo
- Laboratorio Cellule Staminali Post Natali e Terapie Cellulari, Istituto Giannina Gaslini, Genova, Italy
| | - Valeria Poli
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Ferdinando Di Cunto
- Neuroscience Institute Cavalieri Ottolenghi, Regione Gonzole 10, 10043, Orbassano (TO), Italy
| | - Alessandra Eva
- Laboratory of Molecular Biology, Giannina Gaslini Institute, 16147, Genova, Italy
| | - Chiara Riganti
- Department of Oncology, University of Torino, 10126, Torino, Italy
| | - Luigi Varesio
- Laboratory of Molecular Biology, Giannina Gaslini Institute, 16147, Genova, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy.
| |
Collapse
|
21
|
Costa TDF, Zhuang T, Lorent J, Turco E, Olofsson H, Masia-Balague M, Zhao M, Rabieifar P, Robertson N, Kuiper R, Sjölund J, Spiess M, Hernández-Varas P, Rabenhorst U, Roswall P, Ma R, Gong X, Hartman J, Pietras K, Adams PD, Defilippi P, Strömblad S. PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer. Nat Commun 2019; 10:3589. [PMID: 31399573 PMCID: PMC6689091 DOI: 10.1038/s41467-019-11510-4] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Accepted: 07/17/2019] [Indexed: 01/10/2023] Open
Abstract
Overcoming cellular growth restriction, including the evasion of cellular senescence, is a hallmark of cancer. We report that PAK4 is overexpressed in all human breast cancer subtypes and associated with poor patient outcome. In mice, MMTV-PAK4 overexpression promotes spontaneous mammary cancer, while PAK4 gene depletion delays MMTV-PyMT driven tumors. Importantly, PAK4 prevents senescence-like growth arrest in breast cancer cells in vitro, in vivo and ex vivo, but is not needed in non-immortalized cells, while PAK4 overexpression in untransformed human mammary epithelial cells abrogates H-RAS-V12-induced senescence. Mechanistically, a PAK4 – RELB - C/EBPβ axis controls the senescence-like growth arrest and a PAK4 phosphorylation residue (RELB-Ser151) is critical for RELB-DNA interaction, transcriptional activity and expression of the senescence regulator C/EBPβ. These findings establish PAK4 as a promoter of breast cancer that can overcome oncogene-induced senescence and reveal a selective vulnerability of cancer to PAK4 inhibition. Oncogene induced senescence protects cells from unrestricted growth and cancer. Here, the authors show that PAK4 overrides this senescence in breast cancer cells through phosphorylation of RELB, thereby inhibiting transcription of the senescence regulator C/EBPβ.
Collapse
Affiliation(s)
- Tânia D F Costa
- Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83, Huddinge, Sweden
| | - Ting Zhuang
- Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83, Huddinge, Sweden.,Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, 453003, Henan, P.R. China
| | - Julie Lorent
- Department of Oncology-Pathology, Karolinska Institutet, SE-171 77, Solna, Sweden
| | - Emilia Turco
- Department of Genetics, Biology and Biochemistry, University of Torino, 10126, Torino, Italy
| | - Helene Olofsson
- Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83, Huddinge, Sweden
| | - Miriam Masia-Balague
- Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83, Huddinge, Sweden
| | - Miao Zhao
- Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83, Huddinge, Sweden.,Department of Immunology, Genetics and Pathology, Uppsala University, SE-752 36, Uppsala, Sweden
| | - Parisa Rabieifar
- Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83, Huddinge, Sweden
| | - Neil Robertson
- Beatson Institute for Cancer Research, Bearsden, Glasgow, G61 1BD, UK
| | - Raoul Kuiper
- Department of Laboratory Medicine, Karolinska Institutet, SE-141 57, Huddinge, Sweden
| | - Jonas Sjölund
- Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, SE-223 81, Lund, Sweden
| | - Matthias Spiess
- Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83, Huddinge, Sweden
| | - Pablo Hernández-Varas
- Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83, Huddinge, Sweden
| | - Uta Rabenhorst
- Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83, Huddinge, Sweden
| | - Pernilla Roswall
- Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77, Solna, Sweden
| | - Ran Ma
- Department of Oncology-Pathology, Karolinska Institutet, SE-171 77, Solna, Sweden
| | - Xiaowei Gong
- Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83, Huddinge, Sweden
| | - Johan Hartman
- Department of Oncology-Pathology, Karolinska Institutet, SE-171 77, Solna, Sweden
| | - Kristian Pietras
- Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, SE-223 81, Lund, Sweden.,Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77, Solna, Sweden
| | - Peter D Adams
- Beatson Institute for Cancer Research, Bearsden, Glasgow, G61 1BD, UK.,Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.,Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Paola Defilippi
- Department of Genetics, Biology and Biochemistry, University of Torino, 10126, Torino, Italy
| | - Staffan Strömblad
- Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83, Huddinge, Sweden.
| |
Collapse
|
22
|
Dettori D, Orso F, Penna E, Baruffaldi D, Brundu S, Maione F, Turco E, Giraudo E, Taverna D. Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models. Mol Ther 2019; 26:2008-2018. [PMID: 29929788 DOI: 10.1016/j.ymthe.2018.05.020] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Revised: 05/21/2018] [Accepted: 05/21/2018] [Indexed: 11/30/2022] Open
Abstract
We previously demonstrated that miR-214 is upregulated in malignant melanomas and triple-negative breast tumors and promotes metastatic dissemination by affecting a complex pathway including the anti-metastatic miR-148b. Importantly, tumor dissemination could be reduced by blocking miR-214 function or increasing miR-148b expression or by simultaneous interventions. Based on this evidence, with the intent to explore the role of miR-214 as a target for therapy, we evaluated the capability of new chemically modified anti-miR-214, R97/R98, to inhibit miR-214 coordinated metastatic traits. Relevantly, when melanoma or breast cancer cells were transfected with R97/R98, anti-miR-214 reduced miR-214 expression and impaired transendothelial migration were observed. Noteworthy, when the same cells were injected in the tail vein of mice, cell extravasation and metastatic nodule formation in lungs were strongly reduced. Thus, suggesting that R97/R98 anti-miR-214 oligonucleotides were able to inhibit tumor cell escaping through the endothelium. More importantly, when R97/R98 anti-miR-214 compounds were systemically delivered to mice carrying melanomas or breast or neuroendocrine pancreatic cancers, a reduced number of circulating tumor cells and lung or lymph node metastasis formation were detected. Similar results were also obtained when AAV8-miR-214 sponges were used in neuroendocrine pancreatic tumors. Based on this evidence, we propose miR-214 as a promising target for anti-metastatic therapies.
Collapse
Affiliation(s)
- Daniela Dettori
- Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy; Department Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Francesca Orso
- Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy; Department Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; Center for Complex Systems in Molecular Biology and Medicine, University of Torino, Torino, Italy.
| | - Elisa Penna
- Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy; Department Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Désirée Baruffaldi
- Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy; Department Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Serena Brundu
- Department of Science and Drug Technology, University of Torino, Torino, Italy; Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Torino, Italy
| | - Federica Maione
- Department of Science and Drug Technology, University of Torino, Torino, Italy; Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Torino, Italy
| | - Emilia Turco
- Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy; Department Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Enrico Giraudo
- Department of Science and Drug Technology, University of Torino, Torino, Italy; Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Torino, Italy
| | - Daniela Taverna
- Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy; Department Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; Center for Complex Systems in Molecular Biology and Medicine, University of Torino, Torino, Italy.
| |
Collapse
|
23
|
Grasso S, Cangelosi D, Chapelle J, Alzona M, Centonze G, Lamolinara A, Salemme V, Angelini C, Morellato A, Saglietto A, Bianchi FT, Cabodi S, Salaroglio IC, Fusella F, Ognibene M, Iezzi M, Pezzolo A, Poli V, Di Cunto F, Eva A, Riganti C, Varesio L, Turco E, Defilippi P. The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma. Cell Death Differ 2019; 27:790-807. [PMID: 31285546 PMCID: PMC7205889 DOI: 10.1038/s41418-019-0386-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Revised: 05/21/2019] [Accepted: 06/21/2019] [Indexed: 01/01/2023] Open
Abstract
Neuroblastoma is the most common extra-cranial pediatric solid tumor, responsible for 13–15% of pediatric cancer death. Its intrinsic heterogeneity makes it difficult to target for successful therapy. The adaptor protein p140Cap/SRCIN1 negatively regulates tumor cell features and limits breast cancer progression. This study wish to assess if p140Cap is a key biological determinant of neuroblastoma outcome. RNAseq profiles of a large cohort of neuroblastoma patients show that SRCIN1 mRNA levels are an independent risk factor inversely correlated to disease aggressiveness. In high-risk patients, CGH+SNP microarray analysis of primary neuroblastoma identifies SRCIN1 as frequently altered by hemizygous deletion, copy-neutral loss of heterozygosity, or disruption. Functional experiments show that p140Cap negatively regulates Src and STAT3 signaling, affects anchorage-independent growth and migration, in vivo tumor growth and spontaneous lung metastasis formation. p140Cap also increases sensitivity of neuroblastoma cells to doxorubicin and etoposide treatment, as well as to a combined treatment with chemotherapy drugs and Src inhibitors. Our functional findings point to a causal role of p140Cap in curbing the aggressiveness of neuroblastoma, due to its ability to impinge on specific molecular pathways, and to sensitize cells to therapeutic treatment. This study provides the first evidence that the SRCIN1/p140Cap adaptor protein is a key player in neuroblastoma as a new independent prognostic marker for patient outcome and treatment. Altogether, these data highlight the potential clinical impact of SRCIN1/p140Cap expression in neuroblastoma tumors, in terms of reducing cytotoxic effects of chemotherapy, one of the main issues for pediatric tumor treatment.
Collapse
Affiliation(s)
- Silvia Grasso
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Davide Cangelosi
- Laboratory of Molecular Biology, Giannina Gaslini Institute, 16147, Genova, Italy
| | - Jennifer Chapelle
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Melissa Alzona
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Giorgia Centonze
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Alessia Lamolinara
- Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, Italy
| | - Vincenzo Salemme
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Costanza Angelini
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Alessandro Morellato
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Andrea Saglietto
- Cardiology Division, Department of Medical Sciences, University of Torino, 10126 Torino, Italy
| | - Federico Tommaso Bianchi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy.,Neuroscience Institute Cavalieri Ottolenghi, Regione Gonzole 10, 10043, Orbassano (TO), Italy
| | - Sara Cabodi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Iris Chiara Salaroglio
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy.,Department of Oncology, University of Torino, 10126, Torino, Italy
| | - Federica Fusella
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Marzia Ognibene
- Laboratorio Cellule Staminali Post Natali e Terapie Cellulari, Istituto Giannina Gaslini, Genova, Italy
| | - Manuela Iezzi
- Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, Italy
| | - Annalisa Pezzolo
- Laboratorio Cellule Staminali Post Natali e Terapie Cellulari, Istituto Giannina Gaslini, Genova, Italy
| | - Valeria Poli
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Ferdinando Di Cunto
- Neuroscience Institute Cavalieri Ottolenghi, Regione Gonzole 10, 10043, Orbassano (TO), Italy
| | - Alessandra Eva
- Laboratory of Molecular Biology, Giannina Gaslini Institute, 16147, Genova, Italy
| | - Chiara Riganti
- Department of Oncology, University of Torino, 10126, Torino, Italy
| | - Luigi Varesio
- Laboratory of Molecular Biology, Giannina Gaslini Institute, 16147, Genova, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy.
| |
Collapse
|
24
|
Sant K, Palcu DV, Turco E, Di Stefano A, Baldassini N, Kouwenhoven T, Kuiper KF, Krijgsman W. Litho- and biostratigraphic data of lower-middle Miocene sections in the Transylvanian basin and SE Carpathian Foredeep (Romania). Data Brief 2019; 24:103904. [PMID: 31193225 PMCID: PMC6525294 DOI: 10.1016/j.dib.2019.103904] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2018] [Revised: 03/16/2019] [Accepted: 03/26/2019] [Indexed: 11/29/2022] Open
Abstract
Litho- and biostratigraphic data are provided of 5 stratigraphic sections in Romania covering the “Badenian” marine flooding that occurred in the Central Paratethys during the middle Miocene (Langhian). The dataset includes stratigraphic logs and descriptions of the profiles, and biostratigraphic analyses on calcareous nannofossils and foraminifera. In addition, characteristic stratigraphic features and representative fossils, including tiny Streptochilus foraminifera in the Campiniţa section in the SE Carpathian Foredeep, are presented in photographs. The data show that the flooding is characterized by the sudden abundance of Langhian calcareous nannofossils and foraminifera with a strong Mediterranean affinity.
Collapse
Affiliation(s)
- K Sant
- Paleomagnetic Laboratory Fort Hoofddijk, Utrecht University, Utrecht, the Netherlands
| | - D V Palcu
- Paleomagnetic Laboratory Fort Hoofddijk, Utrecht University, Utrecht, the Netherlands
| | - E Turco
- Department of Chemistry, Life Sciences and Environmental Sustainability, Parma University, Parma, Italy
| | - A Di Stefano
- Department of Biological, Geological and Environmental Sciences, Catania University, Catania, Italy
| | - N Baldassini
- Department of Biological, Geological and Environmental Sciences, Catania University, Catania, Italy
| | - T Kouwenhoven
- Department of Geosciences, Stratigraphy-Paleontology, Heidelberglaan 2, 3584 CS Utrecht, the Netherlands
| | - K F Kuiper
- Department of Earth Sciences, Vrije Universiteit Amsterdam, the Netherlands
| | - W Krijgsman
- Paleomagnetic Laboratory Fort Hoofddijk, Utrecht University, Utrecht, the Netherlands
| |
Collapse
|
25
|
Costamagna A, Rossi Sebastiano M, Natalini D, Simoni M, Valabrega G, Defilippi P, Visentin S, Ermondi G, Turco E, Caron G, Cabodi S. Modeling ErbB2-p130Cas interaction to design new potential anticancer agents. Sci Rep 2019; 9:3089. [PMID: 30816273 PMCID: PMC6395809 DOI: 10.1038/s41598-019-39510-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Accepted: 01/11/2019] [Indexed: 12/02/2022] Open
Abstract
The ErbB2 receptor tyrosine kinase is overexpressed in approximately 15–20% of breast tumors and associated with aggressive disease and poor clinical outcome. p130Cas represents a nodal scaffold protein regulating cell survival, migration and proliferation in normal and pathological contexts. p130Cas overexpression in ErbB2 human breast cancer correlates with poor prognosis and metastasis formation. Recent data indicate that p130Cas association to ErbB2 protects ErbB2 from degradation, thus enhancing tumorigenesis. Therefore, inhibiting p130Cas/ErbB2 interaction might represent a new therapeutic strategy to target breast cancer. Here we demonstrate by performing Molecular Modeling, Molecular Dynamics, dot blot, ELISA and fluorescence quenching experiments, that p130Cas binds directly to ErbB2. Then, by structure-based virtual screening, we identified two potential inhibitors of p130Cas/ErbB2 interaction. Their experimental validation was performed in vitro and in ErbB2-positive breast cancer cellular models. The results highlight that both compounds interfere with p130Cas/ErbB2 binding and significantly affect cell proliferation and sensitivity to Trastuzumab. Overall, this study identifies p130Cas/ErbB2 complex as a potential breast cancer target revealing new therapeutic perspectives for protein-protein interaction (PPI).
Collapse
Affiliation(s)
- Andrea Costamagna
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | | | - Dora Natalini
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Matilde Simoni
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | | | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Sonja Visentin
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Giuseppe Ermondi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Giulia Caron
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy
| | - Sara Cabodi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
| |
Collapse
|
26
|
Calorio C, Gavello D, Guarina L, Salio C, Sassoè-Pognetto M, Riganti C, Bianchi FT, Hofer NT, Tuluc P, Obermair GJ, Defilippi P, Balzac F, Turco E, Bett GC, Rasmusson RL, Carbone E. Impaired chromaffin cell excitability and exocytosis in autistic Timothy syndrome TS2-neo mouse rescued by L-type calcium channel blockers. J Physiol 2019; 597:1705-1733. [PMID: 30629744 DOI: 10.1113/jp277487] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Accepted: 12/19/2018] [Indexed: 12/30/2022] Open
Abstract
KEY POINTS Tymothy syndrome (TS) is a multisystem disorder featuring cardiac arrhythmias, autism and adrenal gland dysfunction that originates from a de novo point mutation in the gene encoding the Cav1.2 (CACNA1C) L-type channel. To study the role of Cav1.2 channel signals in autism, the autistic TS2-neo mouse has been generated bearing the G406R point-mutation associated with TS type-2. Using heterozygous TS2-neo mice, we report that the G406R mutation reduces the rate of inactivation and shifts leftward the activation and inactivation of L-type channels, causing marked increase of resting Ca2+ influx ('window' Ca2+ current). The increased 'window current' causes marked reduction of NaV channel density, switches normal tonic firing to abnormal burst firing, reduces mitochondrial metabolism, induces cell swelling and decreases catecholamine release. Overnight incubations with nifedipine rescue NaV channel density, normal firing and the quantity of catecholamine released. We provide evidence that chromaffin cell malfunction derives from altered Cav1.2 channel gating. ABSTRACT L-type voltage-gated calcium (Cav1) channels have a key role in long-term synaptic plasticity, sensory transduction, muscle contraction and hormone release. A point mutation in the gene encoding Cav1.2 (CACNA1C) causes Tymothy syndrome (TS), a multisystem disorder featuring cardiac arrhythmias, autism spectrum disorder (ASD) and adrenal gland dysfunction. In the more severe type-2 form (TS2), the missense mutation G406R is on exon 8 coding for the IS6-helix of the Cav1.2 channel. The mutation causes reduced inactivation and induces autism. How this occurs and how Cav1.2 gating-changes alter cell excitability, neuronal firing and hormone release on a molecular basis is still largely unknown. Here, using the TS2-neo mouse model of TS we show that the G406R mutation altered excitability and reduced secretory activity in adrenal chromaffin cells (CCs). Specifically, the TS2 mutation reduced the rate of voltage-dependent inactivation and shifted leftward the activation and steady-state inactivation of L-type channels. This markedly increased the resting 'window' Ca2+ current that caused an increased percentage of CCs undergoing abnormal action potential (AP) burst firing, cell swelling, reduced mitochondrial metabolism and decreased catecholamine release. The increased 'window' Ca2+ current caused also decreased NaV channel density and increased steady-state inactivation, which contributed to the increased abnormal burst firing. Overnight incubation with the L-type channel blocker nifedipine rescued the normal AP firing of CCs, the density of functioning NaV channels and their steady-state inactivation. We provide evidence that CC malfunction derives from the altered Cav1.2 channel gating and that dihydropyridines are potential therapeutics for ASD.
Collapse
Affiliation(s)
- Chiara Calorio
- Department of Drug Science, NIS Centre, University of Torino, Torino, Italy
| | - Daniela Gavello
- Department of Drug Science, NIS Centre, University of Torino, Torino, Italy
| | - Laura Guarina
- Department of Drug Science, NIS Centre, University of Torino, Torino, Italy
| | - Chiara Salio
- Department of Veterinary Sciences, University of Torino, Torino, Italy
| | - Marco Sassoè-Pognetto
- Department of Neuroscience Rita Levi Montalcini, University of Torino, Torino, Italy
| | - Chiara Riganti
- Department of Oncology, University of Torino, Torino, Italy
| | | | - Nadja T Hofer
- Department of Pharmacology and Toxicology, Center for Molecular Biosciences, University of Innsbruck, Innsbruck, Austria
| | - Petronel Tuluc
- Department of Pharmacology and Toxicology, Center for Molecular Biosciences, University of Innsbruck, Innsbruck, Austria
| | - Gerald J Obermair
- Department of Physiology & Medical Physics, Medical University of Innsbruck, Innsbruck, Austria
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Fiorella Balzac
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Glenna C Bett
- Department of Physiology & Biophysics, State University of New York, Buffalo, NY, USA
| | - Randall L Rasmusson
- Department of Physiology & Biophysics, State University of New York, Buffalo, NY, USA
| | - Emilio Carbone
- Department of Drug Science, NIS Centre, University of Torino, Torino, Italy
| |
Collapse
|
27
|
Del Pilar Camacho Leal M, Costamagna A, Tassone B, Saoncella S, Simoni M, Natalini D, Dadone A, Sciortino M, Turco E, Defilippi P, Calautti E, Cabodi S. Correction to: Conditional ablation of p130Cas/BCAR1 adaptor protein impairs epidermal homeostasis by altering cell adhesion and differentiation. Cell Commun Signal 2018; 16:90. [PMID: 30477510 PMCID: PMC6258440 DOI: 10.1186/s12964-018-0296-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Accepted: 11/07/2018] [Indexed: 11/10/2022] Open
Affiliation(s)
- Maria Del Pilar Camacho Leal
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza, 52, Torino, Italy
| | - Andrea Costamagna
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza, 52, Torino, Italy
| | - Beatrice Tassone
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza, 52, Torino, Italy
| | - Stefania Saoncella
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza, 52, Torino, Italy
| | - Matilde Simoni
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza, 52, Torino, Italy
| | - Dora Natalini
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza, 52, Torino, Italy
| | - Aurora Dadone
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza, 52, Torino, Italy
| | - Marianna Sciortino
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza, 52, Torino, Italy
| | - Emilia Turco
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza, 52, Torino, Italy
| | - Paola Defilippi
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza, 52, Torino, Italy
| | - Enzo Calautti
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza, 52, Torino, Italy
| | - Sara Cabodi
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza, 52, Torino, Italy.
| |
Collapse
|
28
|
Grasso S, Chapelle J, Salemme V, Aramu S, Russo I, Vitale N, di Cantogno LV, Dallaglio K, Castellano I, Amici A, Centonze G, Sharma N, Lunardi S, Cabodi S, Cavallo F, Lamolinara A, Stramucci L, Moiso E, Provero P, Albini A, Sapino A, Staaf J, Di Fiore PP, Bertalot G, Pece S, Tosoni D, Confalonieri S, Iezzi M, Di Stefano P, Turco E, Defilippi P. Correction: Author Correction: The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. Nat Commun 2018; 9:16203. [PMID: 29600801 PMCID: PMC5882465 DOI: 10.1038/ncomms16203] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
29
|
Camacho Leal MDP, Costamagna A, Tassone B, Saoncella S, Simoni M, Natalini D, Dadone A, Sciortino M, Turco E, Defilippi P, Calautti E, Cabodi S. Conditional ablation of p130Cas/BCAR1 adaptor protein impairs epidermal homeostasis by altering cell adhesion and differentiation. Cell Commun Signal 2018; 16:73. [PMID: 30390666 PMCID: PMC6215608 DOI: 10.1186/s12964-018-0289-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Accepted: 10/25/2018] [Indexed: 12/20/2022] Open
Abstract
Background p130 Crk-associated substrate (p130CAS; also known as BCAR1) is a scaffold protein that modulates many essential cellular processes such as cell adhesion, proliferation, survival, cell migration, and intracellular signaling. p130Cas has been shown to be highly expressed in a variety of human cancers of epithelial origin. However, few data are available regarding the role of p130Cas during normal epithelial development and homeostasis. Methods To this end, we have generated a genetically modified mouse in which p130Cas protein was specifically ablated in the epidermal tissue. Results By using this murine model, we show that p130Cas loss results in increased cell proliferation and reduction of cell adhesion to extracellular matrix. In addition, epidermal deletion of p130Cas protein leads to premature expression of “late” epidermal differentiation markers, altered membrane E-cadherin/catenin proteins localization and aberrant tyrosine phosphorylation of E-cadherin/catenin complexes. Interestingly, these alterations in adhesive properties in absence of p130Cas correlate with abnormalities in progenitor cells balance resulting in the amplification of a more committed cell population. Conclusion Altogether, these results provide evidence that p130Cas is an important regulator of epidermal cell fate and homeostasis. Electronic supplementary material The online version of this article (10.1186/s12964-018-0289-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Maria Del Pilar Camacho Leal
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza 52, Torino, Italy
| | - Andrea Costamagna
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza 52, Torino, Italy
| | - Beatrice Tassone
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza 52, Torino, Italy
| | - Stefania Saoncella
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza 52, Torino, Italy
| | - Matilde Simoni
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza 52, Torino, Italy
| | - Dora Natalini
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza 52, Torino, Italy
| | - Aurora Dadone
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza 52, Torino, Italy
| | - Marianna Sciortino
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza 52, Torino, Italy
| | - Emilia Turco
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza 52, Torino, Italy
| | - Paola Defilippi
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza 52, Torino, Italy
| | - Enzo Calautti
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza 52, Torino, Italy
| | - Sara Cabodi
- Department of Biotechnology and Health Science, Molecular Biotechnology Center, Università di Torino, Via Nizza 52, Torino, Italy.
| |
Collapse
|
30
|
Mancini C, Hoxha E, Iommarini L, Brussino A, Richter U, Montarolo F, Cagnoli C, Parolisi R, Gondor Morosini DI, Nicolò V, Maltecca F, Muratori L, Ronchi G, Geuna S, Arnaboldi F, Donetti E, Giorgio E, Cavalieri S, Di Gregorio E, Pozzi E, Ferrero M, Riberi E, Casari G, Altruda F, Turco E, Gasparre G, Battersby BJ, Porcelli AM, Ferrero E, Brusco A, Tempia F. Mice harbouring a SCA28 patient mutation in AFG3L2 develop late-onset ataxia associated with enhanced mitochondrial proteotoxicity. Neurobiol Dis 2018; 124:14-28. [PMID: 30389403 DOI: 10.1016/j.nbd.2018.10.018] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2018] [Revised: 10/05/2018] [Accepted: 10/28/2018] [Indexed: 12/20/2022] Open
Abstract
Spinocerebellar ataxia 28 is an autosomal dominant neurodegenerative disorder caused by missense mutations affecting the proteolytic domain of AFG3L2, a major component of the mitochondrial m-AAA protease. However, little is known of the underlying pathogenetic mechanisms or how to treat patients with SCA28. Currently available Afg3l2 mutant mice harbour deletions that lead to severe, early-onset neurological phenotypes that do not faithfully reproduce the late-onset and slowly progressing SCA28 phenotype. Here we describe production and detailed analysis of a new knock-in murine model harbouring an Afg3l2 allele carrying the p.Met665Arg patient-derived mutation. Heterozygous mutant mice developed normally but adult mice showed signs of cerebellar ataxia detectable by beam test. Although cerebellar pathology was negative, electrophysiological analysis showed a trend towards increased spontaneous firing in Purkinje cells from heterozygous mutants with respect to wild-type controls. As homozygous mutants died perinatally with evidence of cardiac atrophy, for each genotype we generated mouse embryonic fibroblasts (MEFs) to investigate mitochondrial function. MEFs from mutant mice showed altered mitochondrial bioenergetics, with decreased basal oxygen consumption rate, ATP synthesis and mitochondrial membrane potential. Mitochondrial network formation and morphology was altered, with greatly reduced expression of fusogenic Opa1 isoforms. Mitochondrial alterations were also detected in cerebella of 18-month-old heterozygous mutants and may be a hallmark of disease. Pharmacological inhibition of de novo mitochondrial protein translation with chloramphenicol caused reversal of mitochondrial morphology in homozygous mutant MEFs, supporting the relevance of mitochondrial proteotoxicity for SCA28 pathogenesis and therapy development.
Collapse
Affiliation(s)
- Cecilia Mancini
- Department of Medical Sciences, University of Torino, Torino, Italy
| | - Eriola Hoxha
- Department of Neuroscience, University of Torino, Torino, Italy; Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Italy
| | - Luisa Iommarini
- Department of Pharmacy and Biotechnologies (FABIT), University of Bologna, Bologna, Italy
| | | | - Uwe Richter
- Institute of Biotechnology, University of Helsinki, Helsinki, Finland
| | - Francesca Montarolo
- Department of Neuroscience, University of Torino, Torino, Italy; Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Italy
| | - Claudia Cagnoli
- Department of Medical Sciences, University of Torino, Torino, Italy
| | - Roberta Parolisi
- Department of Neuroscience, University of Torino, Torino, Italy; Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Italy
| | - Diana Iulia Gondor Morosini
- Department of Neuroscience, University of Torino, Torino, Italy; Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Italy
| | - Valentina Nicolò
- Department of Neuroscience, University of Torino, Torino, Italy; Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Italy
| | - Francesca Maltecca
- Università Vita-Salute San Raffaele, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy
| | - Luisa Muratori
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Italy; Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
| | - Giulia Ronchi
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Italy; Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
| | - Stefano Geuna
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Italy; Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
| | - Francesca Arnaboldi
- Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy
| | - Elena Donetti
- Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy
| | - Elisa Giorgio
- Department of Medical Sciences, University of Torino, Torino, Italy
| | - Simona Cavalieri
- Department of Medical Sciences, University of Torino, Torino, Italy
| | - Eleonora Di Gregorio
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Torino, Italy
| | - Elisa Pozzi
- Department of Medical Sciences, University of Torino, Torino, Italy
| | - Marta Ferrero
- Department of Medical Sciences, University of Torino, Torino, Italy
| | - Evelise Riberi
- Department of Public Health and Pediatrics, University of Torino, Torino, Italy
| | - Giorgio Casari
- Università Vita-Salute San Raffaele, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy
| | - Fiorella Altruda
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Emilia Turco
- Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | - Giuseppe Gasparre
- Department Medical and Surgical Sciences, Medical Genetics, University of Bologna, Bologna, Italy
| | | | - Anna Maria Porcelli
- Department of Pharmacy and Biotechnologies (FABIT), University of Bologna, Bologna, Italy
| | - Enza Ferrero
- Department of Medical Sciences, University of Torino, Torino, Italy
| | - Alfredo Brusco
- Department of Medical Sciences, University of Torino, Torino, Italy; Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Torino, Italy.
| | - Filippo Tempia
- Department of Neuroscience, University of Torino, Torino, Italy; Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Italy
| |
Collapse
|
31
|
Canosa A, De Marco G, Lomartire A, Rinaudo MT, Di Cunto F, Turco E, Barberis M, Brunetti M, Casale F, Moglia C, Calvo A, Marklund SL, Andersen PM, Mora G, Chiò A. A novel p.Ser108LeufsTer15 SOD1 mutation leading to the formation of a premature stop codon in an apparently sporadic ALS patient: insights into the underlying pathomechanisms. Neurobiol Aging 2018; 72:189.e11-189.e17. [PMID: 30236613 DOI: 10.1016/j.neurobiolaging.2018.08.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Revised: 07/12/2018] [Accepted: 08/15/2018] [Indexed: 12/14/2022]
Abstract
We report an apparently sporadic amyotrophic lateral sclerosis patient carrying a heterozygous novel frameshift SOD1 mutation (p.Ser108LeufsTer15), predicted to cause a premature protein truncation. RT-PCR analysis of SOD1 mRNA and SDS-PAGE/Western blot analysis of PBMC demonstrated that mRNA from the mutant allele is expressed at levels similar to those of the wild-type allele, but the truncated protein is undetectable also in the insoluble fraction and after proteasome inhibition. Accordingly, the dismutation activity in erythrocytes is halved. Thus, the pathogenic mechanism associated with this mutation might be based on an insufficient activity of SOD1 that would make motor neurons more vulnerable to oxidative injury. However, it cannot be excluded that p.Ser108LeufsTer15 SOD1 is present in the nervous tissue and, being less charged and hence having less repulsive forces than the wild-type protein, may trigger toxic mechanisms as a consequence of its propensity to aggregate.
Collapse
Affiliation(s)
- Antonio Canosa
- ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy.
| | - Giovanni De Marco
- ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy
| | - Annarosa Lomartire
- ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy
| | | | - Ferdinando Di Cunto
- Neuroscience Institute Cavalieri Ottolenghi, University of Turin, Orbassano, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Marco Barberis
- ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy
| | - Maura Brunetti
- ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy
| | - Federico Casale
- ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy
| | - Cristina Moglia
- ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, S.C. Neurologia 2 U, Turin, Italy
| | - Andrea Calvo
- ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, S.C. Neurologia 2 U, Turin, Italy; Neuroscience Institute of Turin (NIT), Turin, Italy
| | - Stefan L Marklund
- Department of Pharmacology and Clinical Neurosciences, Umeå University, Umeå, Sweden
| | - Peter M Andersen
- Department of Medical Biosciences, Clinical Chemistry, Umeå University, Umeå, Sweden
| | - Gabriele Mora
- ALS Centre, "Salvatore Maugeri" Clinical-Scientific Institutes, IRCCS, Neurological Rehabilitation Unit, Milan, Italy
| | - Adriano Chiò
- ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Turin, Italy; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, S.C. Neurologia 2 U, Turin, Italy; Neuroscience Institute of Turin (NIT), Turin, Italy; Institute of Cognitive Sciences and Technologies, C.N.R, Rome, Italy
| |
Collapse
|
32
|
Giorgio I, Harrison P, dell'Isola F, Alsayednoor J, Turco E. Wrinkling in engineering fabrics: a comparison between two different comprehensive modelling approaches. Proc Math Phys Eng Sci 2018; 474:20180063. [PMID: 30220866 PMCID: PMC6127399 DOI: 10.1098/rspa.2018.0063] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 07/12/2018] [Indexed: 11/12/2022] Open
Abstract
We consider two 'comprehensive' modelling approaches for engineering fabrics. We distinguish the two approaches using the terms 'semi-discrete' and 'continuum', reflecting their natures. We demonstrate a fitting procedure, used to identify the constitutive parameters of the continuum model from predictions of the semi-discrete model, the parameters of which are in turn fitted to experimental data. We, then, check the effectiveness of the continuum model by verifying the correspondence between semi-discrete and continuum model predictions using test cases not previously used in the identification process. Predictions of both modelling approaches are compared against full-field experimental kinematic data, obtained using stereoscopic digital image correlation techniques, and also with measured force data. Being a reduced order model and being implemented in an implicit rather than an explicit finite-element code, the continuum model requires significantly less computational power than the semi-discrete model and could therefore be used to more efficiently explore the mechanical response of engineering fabrics.
Collapse
Affiliation(s)
- I Giorgio
- DISG, Università di Roma La Sapienza, Rome, Italy.,International Research Center, M&MoCS, L'Aquila, Italy
| | - P Harrison
- School of Engineering, University of Glasgow, Glasgow, UK.,International Research Center, M&MoCS, L'Aquila, Italy
| | - F dell'Isola
- DISG, Università di Roma La Sapienza, Rome, Italy.,International Research Center, M&MoCS, L'Aquila, Italy
| | - J Alsayednoor
- School of Engineering, University of Glasgow, Glasgow, UK
| | - E Turco
- Department of Architecture, Design and Urban planning, University of Sassari, Alghero, Italy.,International Research Center, M&MoCS, L'Aquila, Italy
| |
Collapse
|
33
|
Pallavicini G, Sgrò F, Garello F, Falcone M, Bitonto V, Berto GE, Bianchi FT, Gai M, Chiotto AM, Filippi M, Cutrin JC, Ala U, Terreno E, Turco E, Cunto FD. Inactivation of Citron Kinase Inhibits Medulloblastoma Progression by Inducing Apoptosis and Cell Senescence. Cancer Res 2018; 78:4599-4612. [DOI: 10.1158/0008-5472.can-17-4060] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2017] [Revised: 05/01/2018] [Accepted: 06/07/2018] [Indexed: 11/16/2022]
|
34
|
Rocca S, D’Anna F, Fusella F, Orso F, Ala U, Provero P, Taverna D, Turco E, Brancaccio M. PO-356 MicroRNA mediated regulation of morgana, a new oncosuppressor in chronic myeloid leukaemia. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
35
|
Seclì L, Fusella F, Fragale G, Rubinetto C, Rocca S, Turco E, Brancaccio M. PO-237 Neutralising extracellular morgana impairs breast tumour growth and migration. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
36
|
Porta C, Ippolito A, Consonni FM, Carraro L, Celesti G, Correale C, Grizzi F, Pasqualini F, Tartari S, Rinaldi M, Bianchi P, Balzac F, Vetrano S, Turco E, Hirsch E, Laghi L, Sica A. Protumor Steering of Cancer Inflammation by p50 NF-κB Enhances Colorectal Cancer Progression. Cancer Immunol Res 2018; 6:578-593. [PMID: 29588321 DOI: 10.1158/2326-6066.cir-17-0036] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Revised: 11/27/2017] [Accepted: 03/09/2018] [Indexed: 12/23/2022]
Abstract
Although tumor-associated macrophages (TAM) display a M2-skewed tumor-promoting phenotype in most cancers, in colorectal cancer, both TAM polarization and its impact remain controversial. We investigated the role of the M2-polarizing p50 NF-κB subunit in orchestrating TAM phenotype, tumor microenvironment composition, and colorectal cancer progression. We first demonstrated, by parallel studies in colitis-associated cancer (CAC) and in genetically driven ApcMin mouse models, that the p50-dependent inhibition of M1-polarized gut inflammation supported colorectal cancer development. In accordance with these studies, p50-/- mice displayed exacerbated CAC with fewer and smaller tumors, along with enhanced levels of M1/Th1 cytokines/chemokines, including IL12 and CXCL10, whose administration restrained CAC development in vivo The inflammatory profile supporting tumor resistance in colons from p50-/- tumor bearers correlated inversely with TAM load and positively with both recruitment of NK, NKT, CD8+ T cells and number of apoptotic tumor cells. In agreement, myeloid-specific ablation of p50 promoted tumor resistance in mice, whereas in colorectal cancer patients, a high number of p50+ TAMs at the invasive margin was associated with decreased IL12A and TBX21 expression and worse postsurgical outcome. Our findings point to p50 involvement in colorectal cancer development, through its engagement in the protumor activation of macrophages, and identify a candidate for prognostic and target therapeutic intervention. Cancer Immunol Res; 6(5); 578-93. ©2018 AACR.
Collapse
Affiliation(s)
- Chiara Porta
- Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale "Amedeo Avogadro," Novara, Italy.
| | - Alessandro Ippolito
- Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale "Amedeo Avogadro," Novara, Italy
| | - Francesca Maria Consonni
- Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale "Amedeo Avogadro," Novara, Italy
| | - Lorenzo Carraro
- Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale "Amedeo Avogadro," Novara, Italy
| | | | | | - Fabio Grizzi
- Humanitas Clinical and Research Center, Rozzano, Italy
| | | | | | - Maurizio Rinaldi
- Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale "Amedeo Avogadro," Novara, Italy
| | - Paolo Bianchi
- Humanitas Clinical and Research Center, Rozzano, Italy
| | - Fiorella Balzac
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Torino, Italy
| | | | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Torino, Italy
| | - Emilio Hirsch
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Torino, Italy
| | - Luigi Laghi
- Humanitas Clinical and Research Center, Rozzano, Italy
| | - Antonio Sica
- Department of Pharmaceutical Sciences, Università degli Studi del Piemonte Orientale "Amedeo Avogadro," Novara, Italy. .,Humanitas Clinical and Research Center, Rozzano, Italy
| |
Collapse
|
37
|
Abstract
A nonlinear two-dimensional (2D) continuum with a latent internal structure is introduced as a coarse model of a plane network of beams which, in turn, is assumed as a model of a pantographic structure made up by two families of equispaced beams, superimposed and connected by pivots. The deformation measures of the beams of the network and that of the 2D body are introduced and the former are expressed in terms of the latter by making some kinematical assumptions. The expressions for the strain and kinetic energy densities of the network are then introduced and given in terms of the kinematic quantities of the 2D continuum. To account for the modelling abilities of the 2D continuum in the linear range, the eigenmode and eigenfrequencies of a given specimen are determined. The buckling and post-buckling behaviour of the same specimen, subjected to two different loading conditions are analysed as tests in the nonlinear range. The problems have been solved numerically by means of the COMSOL Multiphysics finite element software.
Collapse
Affiliation(s)
- I. Giorgio
- International Research Center, M&MoCS, L’Aquila, Italy
| | - N. L. Rizzi
- International Research Center, M&MoCS, L’Aquila, Italy
- Department of Architecture, Roma Tre University, Rome, Italy
| | - E. Turco
- International Research Center, M&MoCS, L’Aquila, Italy
- Department of Architecture, Design and Urban planning, University of Sassari, Alghero, Italy
| |
Collapse
|
38
|
Longa C, Nicola L, Antonielli L, Mescalchin E, Zanzotti R, Turco E, Pertot I. Soil microbiota respond to green manure in organic vineyards. J Appl Microbiol 2017; 123:1547-1560. [DOI: 10.1111/jam.13606] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2017] [Revised: 09/05/2017] [Accepted: 10/03/2017] [Indexed: 02/04/2023]
Affiliation(s)
- C.M.O. Longa
- Research and Innovation Centre Fondazione Edmund Mach (FEM) San Michele all' Adige (TN) Italy
| | - L. Nicola
- Research and Innovation Centre Fondazione Edmund Mach (FEM) San Michele all' Adige (TN) Italy
| | - L. Antonielli
- Research and Innovation Centre Fondazione Edmund Mach (FEM) San Michele all' Adige (TN) Italy
| | - E. Mescalchin
- Research and Innovation Centre Fondazione Edmund Mach (FEM) San Michele all' Adige (TN) Italy
| | - R. Zanzotti
- Research and Innovation Centre Fondazione Edmund Mach (FEM) San Michele all' Adige (TN) Italy
| | - E. Turco
- Research and Innovation Centre Fondazione Edmund Mach (FEM) San Michele all' Adige (TN) Italy
| | - I. Pertot
- Research and Innovation Centre Fondazione Edmund Mach (FEM) San Michele all' Adige (TN) Italy
| |
Collapse
|
39
|
Alfieri A, Sorokina O, Adrait A, Angelini C, Russo I, Morellato A, Matteoli M, Menna E, Boeri Erba E, McLean C, Armstrong JD, Ala U, Buxbaum JD, Brusco A, Couté Y, De Rubeis S, Turco E, Defilippi P. Synaptic Interactome Mining Reveals p140Cap as a New Hub for PSD Proteins Involved in Psychiatric and Neurological Disorders. Front Mol Neurosci 2017; 10:212. [PMID: 28713243 PMCID: PMC5492163 DOI: 10.3389/fnmol.2017.00212] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Accepted: 06/15/2017] [Indexed: 01/21/2023] Open
Abstract
Altered synaptic function has been associated with neurological and psychiatric conditions including intellectual disability, schizophrenia and autism spectrum disorder (ASD). Amongst the recently discovered synaptic proteins is p140Cap, an adaptor that localizes at dendritic spines and regulates their maturation and physiology. We recently showed that p140Cap knockout mice have cognitive deficits, impaired long-term potentiation (LTP) and long-term depression (LTD), and immature, filopodia-like dendritic spines. Only a few p140Cap interacting proteins have been identified in the brain and the molecular complexes and pathways underlying p140Cap synaptic function are largely unknown. Here, we isolated and characterized the p140Cap synaptic interactome by co-immunoprecipitation from crude mouse synaptosomes, followed by mass spectrometry-based proteomics. We identified 351 p140Cap interactors and found that they cluster to sub complexes mostly located in the postsynaptic density (PSD). p140Cap interactors converge on key synaptic processes, including transmission across chemical synapses, actin cytoskeleton remodeling and cell-cell junction organization. Gene co-expression data further support convergent functions: the p140Cap interactors are tightly co-expressed with each other and with p140Cap. Importantly, the p140Cap interactome and its co-expression network show strong enrichment in genes associated with schizophrenia, autism, bipolar disorder, intellectual disability and epilepsy, supporting synaptic dysfunction as a shared biological feature in brain diseases. Overall, our data provide novel insights into the molecular organization of the synapse and indicate that p140Cap acts as a hub for postsynaptic complexes relevant to psychiatric and neurological disorders.
Collapse
Affiliation(s)
- Annalisa Alfieri
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Università di TorinoTorino, Italy
| | - Oksana Sorokina
- The Institute for Adaptive and Neural Computation, School of Informatics, University of EdinburghEdinburgh, United Kingdom
| | - Annie Adrait
- Université Grenoble Alpes, iRTSV-BGEGrenoble, France.,CEA, iRTSV-BGEGrenoble, France.,Institut National de la Santé et de la Recherche Médicale, BGEGrenoble, France
| | - Costanza Angelini
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Università di TorinoTorino, Italy
| | - Isabella Russo
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Università di TorinoTorino, Italy
| | - Alessandro Morellato
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Università di TorinoTorino, Italy
| | - Michela Matteoli
- Institute of Neuroscience, Consiglio Nazionale delle Ricerche (CNR)Milan, Italy.,Humanitas Clinical and Research Center, IRCCSRozzano, Italy
| | - Elisabetta Menna
- Institute of Neuroscience, Consiglio Nazionale delle Ricerche (CNR)Milan, Italy.,Humanitas Clinical and Research Center, IRCCSRozzano, Italy
| | - Elisabetta Boeri Erba
- Institut de Biologie Structurale, Université Grenoble AlpesGrenoble, France.,CEA, DSV, IBSGrenoble, France.,Centre National de la Recherche Scientifique, IBSGrenoble, France
| | - Colin McLean
- The Institute for Adaptive and Neural Computation, School of Informatics, University of EdinburghEdinburgh, United Kingdom
| | - J Douglas Armstrong
- The Institute for Adaptive and Neural Computation, School of Informatics, University of EdinburghEdinburgh, United Kingdom
| | - Ugo Ala
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Università di TorinoTorino, Italy.,GenoBiToUS-Genomics and Bioinformatics, Università di TorinoTurin, Italy
| | - Joseph D Buxbaum
- Seaver Autism Center for Research and Treatment, Department of Psychiatry, Icahn School of Medicine at Mount SinaiNew York, NY, United States.,Department of Psychiatry, Icahn School of Medicine at Mount SinaiNew York, NY, United States.,Department of Neuroscience, Icahn School of Medicine at Mount SinaiNew York, NY, United States.,Friedman Brain Institute, Icahn School of Medicine at Mount SinaiNew York, NY, United States.,Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount SinaiNew York, NY, United States.,Mindich Child Health and Development Institute, Icahn School of Medicine at Mount SinaiNew York, NY, United States
| | - Alfredo Brusco
- Department of Medical Sciences, Università di TorinoTurin, Italy.,Medical Genetics Unit, Azienda Ospedaliera Città della Salute e della Scienza di TorinoTurin, Italy
| | - Yohann Couté
- Université Grenoble Alpes, iRTSV-BGEGrenoble, France.,CEA, iRTSV-BGEGrenoble, France.,Institut National de la Santé et de la Recherche Médicale, BGEGrenoble, France
| | - Silvia De Rubeis
- Seaver Autism Center for Research and Treatment, Department of Psychiatry, Icahn School of Medicine at Mount SinaiNew York, NY, United States.,Department of Psychiatry, Icahn School of Medicine at Mount SinaiNew York, NY, United States
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Università di TorinoTorino, Italy
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Università di TorinoTorino, Italy
| |
Collapse
|
40
|
Pallavicini G, Sgrò F, Garello F, Bitonto V, Falcone M, Cutrin JC, Terreno E, Turco E, Cunto FD. MEDU-19. CITRON KINASE AS THERAPEUTIC TARGET FOR MEDULLOBLASTOMA. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox083.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Grasso S, Chapelle J, Salemme V, Aramu S, Russo I, Vitale N, Verdun di Cantogno L, Dallaglio K, Castellano I, Amici A, Centonze G, Sharma N, Lunardi S, Cabodi S, Cavallo F, Lamolinara A, Stramucci L, Moiso E, Provero P, Albini A, Sapino A, Staaf J, Di Fiore PP, Bertalot G, Pece S, Tosoni D, Confalonieri S, Iezzi M, Di Stefano P, Turco E, Defilippi P. The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. Nat Commun 2017; 8:14797. [PMID: 28300085 PMCID: PMC5357316 DOI: 10.1038/ncomms14797] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Accepted: 01/27/2017] [Indexed: 12/29/2022] Open
Abstract
The docking protein p140Cap negatively regulates tumour cell features. Its relevance on breast cancer patient survival, as well as its ability to counteract relevant cancer signalling pathways, are not fully understood. Here we report that in patients with ERBB2-amplified breast cancer, a p140Cap-positive status associates with a significantly lower probability of developing a distant event, and a clear difference in survival. p140Cap dampens ERBB2-positive tumour cell progression, impairing tumour onset and growth in the NeuT mouse model, and counteracting epithelial mesenchymal transition, resulting in decreased metastasis formation. One major mechanism is the ability of p140Cap to interfere with ERBB2-dependent activation of Rac GTPase-controlled circuitries. Our findings point to a specific role of p140Cap in curbing the aggressiveness of ERBB2-amplified breast cancers and suggest that, due to its ability to impinge on specific molecular pathways, p140Cap may represent a predictive biomarker of response to targeted anti-ERBB2 therapies. p140Cap adaptor proteins interfere with adhesion and growth factor-dependent signalling in cancer cells but the mechanisms are unclear. Here the authors show that p140Cap interferes with ERBB2-dependent activation of Rac GTPase-controlled circuitries reducing metastasis and cancer progression.
Collapse
Affiliation(s)
- Silvia Grasso
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Jennifer Chapelle
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Vincenzo Salemme
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Simona Aramu
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Isabella Russo
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Nicoletta Vitale
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | | | - Katiuscia Dallaglio
- Research Infrastructure, IRCCS Arcispedale Santa Maria Nuova, 42100 Reggio Emilia, Italy
| | | | - Augusto Amici
- Department of Bioscience and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy
| | - Giorgia Centonze
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Nanaocha Sharma
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Serena Lunardi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Sara Cabodi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Federica Cavallo
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Alessia Lamolinara
- Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, 66100 Chieti, Italy
| | - Lorenzo Stramucci
- Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, 66100 Chieti, Italy
| | - Enrico Moiso
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Paolo Provero
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Adriana Albini
- Scientific and Technology Pole, IRCCS MultiMedica, 20100 Milan, Italy
| | - Anna Sapino
- Department of Medical Sciences, University of Torino, 10126 Torino, Italy
| | - Johan Staaf
- Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund 22100, Sweden
| | - Pier Paolo Di Fiore
- Molecular Medicine Program, European Institute of Oncology, 20100 Milan, Italy.,IFOM, The FIRC Institute for Molecular Oncology Foundation, 20100 Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, 20100 Milan, Italy
| | - Giovanni Bertalot
- Molecular Medicine Program, European Institute of Oncology, 20100 Milan, Italy
| | - Salvatore Pece
- Molecular Medicine Program, European Institute of Oncology, 20100 Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, 20100 Milan, Italy
| | - Daniela Tosoni
- Molecular Medicine Program, European Institute of Oncology, 20100 Milan, Italy
| | - Stefano Confalonieri
- Molecular Medicine Program, European Institute of Oncology, 20100 Milan, Italy.,IFOM, The FIRC Institute for Molecular Oncology Foundation, 20100 Milan, Italy
| | - Manuela Iezzi
- Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, 66100 Chieti, Italy
| | - Paola Di Stefano
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| | - Paola Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
| |
Collapse
|
42
|
Sgrò F, Bianchi FT, Falcone M, Pallavicini G, Gai M, Chiotto AMA, Berto GE, Turco E, Chang YJ, Huttner WB, Di Cunto F. Tissue-specific control of midbody microtubule stability by Citron kinase through modulation of TUBB3 phosphorylation. Cell Death Differ 2015; 23:801-13. [PMID: 26586574 DOI: 10.1038/cdd.2015.142] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2015] [Revised: 09/13/2015] [Accepted: 09/29/2015] [Indexed: 01/02/2023] Open
Abstract
Cytokinesis, the physical separation of daughter cells at the end of cell cycle, is commonly considered a highly stereotyped phenomenon. However, in some specialized cells this process may involve specific molecular events that are still largely unknown. In mammals, loss of Citron-kinase (CIT-K) leads to massive cytokinesis failure and apoptosis only in neuronal progenitors and in male germ cells, resulting in severe microcephaly and testicular hypoplasia, but the reasons for this specificity are unknown. In this report we show that CIT-K modulates the stability of midbody microtubules and that the expression of tubulin β-III (TUBB3) is crucial for this phenotype. We observed that TUBB3 is expressed in proliferating CNS progenitors, with a pattern correlating with the susceptibility to CIT-K loss. More importantly, depletion of TUBB3 in CIT-K-dependent cells makes them resistant to CIT-K loss, whereas TUBB3 overexpression increases their sensitivity to CIT-K knockdown. The loss of CIT-K leads to a strong decrease in the phosphorylation of S444 on TUBB3, a post-translational modification associated with microtubule stabilization. CIT-K may promote this event by interacting with TUBB3 and by recruiting at the midbody casein kinase-2α (CK2α) that has previously been reported to phosphorylate the S444 residue. Indeed, CK2α is lost from the midbody in CIT-K-depleted cells. Moreover, expression of the nonphosphorylatable TUBB3 mutant S444A induces cytokinesis failure, whereas expression of the phospho-mimetic mutant S444D rescues the cytokinesis failure induced by both CIT-K and CK2α loss. Altogether, our findings reveal that expression of relatively low levels of TUBB3 in mitotic cells can be detrimental for their cytokinesis and underscore the importance of CIT-K in counteracting this event.
Collapse
Affiliation(s)
- F Sgrò
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - F T Bianchi
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - M Falcone
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - G Pallavicini
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - M Gai
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - A M A Chiotto
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - G E Berto
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - E Turco
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Y J Chang
- Max-Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
| | - W B Huttner
- Max-Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
| | - F Di Cunto
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.,Neuroscience Institute of Turin, Turin, Italy
| |
Collapse
|
43
|
Vigliarolo T, Guida L, Millo E, Fresia C, Turco E, De Flora A, Zocchi E. Abscisic acid transport in human erythrocytes. J Biol Chem 2015; 290:13042-52. [PMID: 25847240 DOI: 10.1074/jbc.m114.629501] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2014] [Indexed: 11/06/2022] Open
Abstract
Abscisic acid (ABA) is a plant hormone involved in the response to environmental stress. Recently, ABA has been shown to be present and active also in mammals, where it stimulates the functional activity of innate immune cells, of mesenchymal and hemopoietic stem cells, and insulin-releasing pancreatic β-cells. LANCL2, the ABA receptor in mammalian cells, is a peripheral membrane protein that localizes at the intracellular side of the plasma membrane. Here we investigated the mechanism enabling ABA transport across the plasmamembrane of human red blood cells (RBC). Both influx and efflux of [(3)H]ABA occur across intact RBC, as detected by radiometric and chromatographic methods. ABA binds specifically to Band 3 (the RBC anion transporter), as determined by labeling of RBC membranes with biotinylated ABA. Proteoliposomes reconstituted with human purified Band 3 transport [(3)H]ABA and [(35)S]sulfate, and ABA transport is sensitive to the specific Band 3 inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid. Once inside RBC, ABA stimulates ATP release through the LANCL2-mediated activation of adenylate cyclase. As ATP released from RBC is known to exert a vasodilator response, these results suggest a role for plasma ABA in the regulation of vascular tone.
Collapse
Affiliation(s)
- Tiziana Vigliarolo
- From the Department of Experimental Medicine, Section of Biochemistry, and
| | - Lucrezia Guida
- From the Department of Experimental Medicine, Section of Biochemistry, and
| | - Enrico Millo
- the Center of Excellence for Biomedical Research, University of Genova, Genova 16132, Italy and
| | - Chiara Fresia
- From the Department of Experimental Medicine, Section of Biochemistry, and
| | - Emilia Turco
- the Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy
| | - Antonio De Flora
- From the Department of Experimental Medicine, Section of Biochemistry, and
| | - Elena Zocchi
- From the Department of Experimental Medicine, Section of Biochemistry, and
| |
Collapse
|
44
|
Fossati G, Morini R, Corradini I, Antonucci F, Trepte P, Edry E, Sharma V, Papale A, Pozzi D, Defilippi P, Meier JC, Brambilla R, Turco E, Rosenblum K, Wanker EE, Ziv NE, Menna E, Matteoli M. Reduced SNAP-25 increases PSD-95 mobility and impairs spine morphogenesis. Cell Death Differ 2015; 22:1425-36. [PMID: 25678324 DOI: 10.1038/cdd.2014.227] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Revised: 10/22/2014] [Accepted: 11/26/2014] [Indexed: 12/24/2022] Open
Abstract
Impairment of synaptic function can lead to neuropsychiatric disorders collectively referred to as synaptopathies. The SNARE protein SNAP-25 is implicated in several brain pathologies and, indeed, brain areas of psychiatric patients often display reduced SNAP-25 expression. It has been recently found that acute downregulation of SNAP-25 in brain slices impairs long-term potentiation; however, the processes through which this occurs are still poorly defined. We show that in vivo acute downregulation of SNAP-25 in CA1 hippocampal region affects spine number. Consistently, hippocampal neurons from SNAP-25 heterozygous mice show reduced densities of dendritic spines and defective PSD-95 dynamics. Finally, we show that, in brain, SNAP-25 is part of a molecular complex including PSD-95 and p140Cap, with p140Cap being capable to bind to both SNAP-25 and PSD-95. These data demonstrate an unexpected role of SNAP-25 in controlling PSD-95 clustering and open the possibility that genetic reductions of the protein levels - as occurring in schizophrenia - may contribute to the pathology through an effect on postsynaptic function and plasticity.
Collapse
Affiliation(s)
- G Fossati
- 1] Department of Biotechnology and Translational Medicine, University of Milan, Milano 20129, Italy [2] Humanitas Clinical and Research Center, Laboratory of Pharmacology and Brain Pathology, Via Manzoni 56, Rozzano, 20089 Milano, Italy
| | - R Morini
- 1] Department of Biotechnology and Translational Medicine, University of Milan, Milano 20129, Italy [2] Humanitas Clinical and Research Center, Laboratory of Pharmacology and Brain Pathology, Via Manzoni 56, Rozzano, 20089 Milano, Italy
| | - I Corradini
- 1] Department of Biotechnology and Translational Medicine, University of Milan, Milano 20129, Italy [2] Istituto di Neuroscienze del CNR, Milano 20129, Italy
| | - F Antonucci
- 1] Department of Biotechnology and Translational Medicine, University of Milan, Milano 20129, Italy [2] Istituto di Neuroscienze del CNR, Milano 20129, Italy
| | - P Trepte
- Neuroproteomics, Max Delbrueck Center for Molecular Medicine (MDC), Berlin 13125, Germany
| | - E Edry
- Sagol Department of Neurobiology, Center for Gene Manipulation in the Adult Brain (CGMB), Haifa University, Haifa, Israel
| | - V Sharma
- Sagol Department of Neurobiology, Center for Gene Manipulation in the Adult Brain (CGMB), Haifa University, Haifa, Israel
| | - A Papale
- Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute and University, Milano 20132, Italy
| | - D Pozzi
- Humanitas Clinical and Research Center, Laboratory of Pharmacology and Brain Pathology, Via Manzoni 56, Rozzano, 20089 Milano, Italy
| | - P Defilippi
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10124, Italy
| | - J C Meier
- 1] RNA Editing and Hyperexcitability Disorders Helmholtz Group, Max Delbrück Center for Molecular Medicine, Berlin, Germany [2] TU Braunschweig, Zoological Institute, Division of Cell Biology and Cell Physiology, Braunschweig, Germany
| | - R Brambilla
- Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute and University, Milano 20132, Italy
| | - E Turco
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10124, Italy
| | - K Rosenblum
- Sagol Department of Neurobiology, Center for Gene Manipulation in the Adult Brain (CGMB), Haifa University, Haifa, Israel
| | - E E Wanker
- Neuroproteomics, Max Delbrueck Center for Molecular Medicine (MDC), Berlin 13125, Germany
| | - N E Ziv
- Network Biology Labs and Faculty of Medicine, Technion, 33000 Haifa, Israel
| | - E Menna
- 1] Humanitas Clinical and Research Center, Laboratory of Pharmacology and Brain Pathology, Via Manzoni 56, Rozzano, 20089 Milano, Italy [2] Istituto di Neuroscienze del CNR, Milano 20129, Italy
| | - M Matteoli
- 1] Department of Biotechnology and Translational Medicine, University of Milan, Milano 20129, Italy [2] Humanitas Clinical and Research Center, Laboratory of Pharmacology and Brain Pathology, Via Manzoni 56, Rozzano, 20089 Milano, Italy
| |
Collapse
|
45
|
Saoncella S, Tassone B, Deklic E, Avolio F, Jon C, Tornillo G, De Luca E, Di Iorio E, Piva R, Cabodi S, Turco E, Pandolfi PP, Calautti E. Nuclear Akt2 opposes limbal keratinocyte stem cell self-renewal by repressing a FOXO-mTORC1 signaling pathway. Stem Cells 2014; 32:754-69. [PMID: 24123662 DOI: 10.1002/stem.1565] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2013] [Revised: 09/13/2013] [Accepted: 09/20/2013] [Indexed: 02/06/2023]
Abstract
Signals downstream of Akt can either favor or oppose stem cell (SC) maintenance, but how this dual role can be achieved is still undefined. Using human limbal keratinocyte stem cells (LKSCs), a SC type used in transplantation therapies for corneal regeneration, we show that Akt signaling is prominent in SC populations both in vivo and in vitro, and that Akt1 promotes while Akt2 opposes SC self-renewal. Noteworthy, loss of Akt2 signaling enhances LKSC maintenance ex vivo, whereas Akt1 depletion anticipates SC exhaustion. Mechanistically, the antagonistic functions of Akt1 and Akt2 in SC control are mainly dictated by their differential subcellular distribution, being nuclear Akt2 selectively implicated in FOXO inhibition. Akt2 downregulation favors LKSC maintenance as a result of a gain of FOXO functions, which attenuates the mechanistic target of rapamycin complex one signaling via tuberous sclerosis one gene induction, and promotes growth factor signaling through Akt1. Consistently, Akt2 deficiency also enhances limbal SCs in vivo. Thus, our findings reveal distinct roles for nuclear versus cytosolic Akt signaling in normal epithelial SC control and suggest that the selective Akt2 inhibition may provide novel pharmacological strategies for human LKSC expansion in therapeutic settings and mechanistic research.
Collapse
Affiliation(s)
- Stefania Saoncella
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Fusella F, Ferretti R, Recupero D, Rocca S, Di Savino A, Tornillo G, Silengo L, Turco E, Cabodi S, Provero P, Pandolfi PP, Sapino A, Tarone G, Brancaccio M. Morgana acts as a proto-oncogene through inhibition of a ROCK-PTEN pathway. J Pathol 2014; 234:152-63. [PMID: 24615293 DOI: 10.1002/path.4341] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2013] [Revised: 02/11/2014] [Accepted: 02/13/2014] [Indexed: 12/22/2022]
Abstract
Morgana/CHP-1 is a ubiquitously expressed protein able to inhibit ROCK II kinase activity. We have previously demonstrated that morgana haploinsufficiency leads to multiple centrosomes, genomic instability, and higher susceptibility to tumour development. While a large fraction of human cancers has shown morgana down-regulation, a small subset of tumours was shown to express high morgana levels. Here we demonstrate that high morgana expression in different breast cancer subtypes correlates with high tumour grade, mitosis number, and lymph node positivity. Moreover, morgana overexpression induces transformation in NIH-3T3 cells and strongly protects them from various apoptotic stimuli. From a mechanistic point of view, we demonstrate that morgana causes PTEN destabilization, by inhibiting ROCK activity, hence triggering the PI3K/AKT survival pathway. In turn, morgana down-regulation in breast cancer cells that express high morgana levels increases PTEN expression and leads to sensitization of cells to chemotherapy.
Collapse
Affiliation(s)
- Federica Fusella
- Department of Biotechnology and Health Sciences, University of Torino, Torino, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Tornillo G, Elia AR, Castellano I, Spadaro M, Bernabei P, Bisaro B, Camacho-Leal MDP, Pincini A, Provero P, Sapino A, Turco E, Defilippi P, Cabodi S. p130Cas alters the differentiation potential of mammary luminal progenitors by deregulating c-Kit activity. Stem Cells 2014; 31:1422-33. [PMID: 23592522 DOI: 10.1002/stem.1403] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2012] [Revised: 03/05/2013] [Accepted: 03/14/2013] [Indexed: 01/02/2023]
Abstract
It has recently been proposed that defective differentiation of mammary luminal progenitors predisposes to basal-like breast cancer. However, the molecular and cellular mechanisms involved are still unclear. Here, we describe that the adaptor protein p130Cas is a crucial regulator of mouse mammary epithelial cell (MMEC) differentiation. Using a transgenic mouse model, we show that forced p130Cas overexpression in the luminal progenitor cell compartment results in the expansion of luminal cells, which aberrantly display basal cell features and reduced differentiation in response to lactogenic stimuli. Interestingly, MMECs overexpressing p130Cas exhibit hyperactivation of the tyrosine kinase receptor c-Kit. In addition, we demonstrate that the constitutive c-Kit activation alone mimics p130Cas overexpression, whereas c-Kit downregulation is sufficient to re-establish proper differentiation of p130Cas overexpressing cells. Overall, our data indicate that high levels of p130Cas, via abnormal c-Kit activation, promote mammary luminal cell plasticity, thus providing the conditions for the development of basal-like breast cancer. Consistently, p130Cas is overexpressed in human triple-negative breast cancer, further suggesting that p130Cas upregulation may be a priming event for the onset of basal-like breast cancer.
Collapse
Affiliation(s)
- Giusy Tornillo
- Department of Molecular Biotechnology and Health Sciences, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Vinchi F, Ingoglia G, Chiabrando D, Mercurio S, Turco E, Silengo L, Altruda F, Tolosano E. Heme exporter FLVCR1a regulates heme synthesis and degradation and controls activity of cytochromes P450. Gastroenterology 2014; 146:1325-38. [PMID: 24486949 PMCID: PMC4000440 DOI: 10.1053/j.gastro.2014.01.053] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/22/2013] [Revised: 01/28/2014] [Accepted: 01/28/2014] [Indexed: 12/05/2022]
Abstract
BACKGROUND & AIMS The liver has one of the highest rates of heme synthesis of any organ. More than 50% of the heme synthesized in the liver is used for synthesis of P450 enzymes, which metabolize exogenous and endogenous compounds that include natural products, hormones, drugs, and carcinogens. Feline leukemia virus subgroup C cellular receptor 1a (FLVCR1a) is plasma membrane heme exporter that is ubiquitously expressed and controls intracellular heme content in hematopoietic lineages. We investigated the role of Flvcr1a in liver function in mice. METHODS We created mice with conditional disruption of Mfsd7b, which encodes Flvcr1a, in hepatocytes (Flvcr1a(fl/fl);alb-cre mice). Mice were analyzed under basal conditions, after phenylhydrazine-induced hemolysis, and after induction of cytochromes P450 synthesis. Livers were collected and analyzed by histologic, quantitative real-time polymerase chain reaction, and immunoblot analyses. Hepatic P450 enzymatic activities were measured. RESULTS Flvcr1a(fl/fl);alb-cre mice accumulated heme and iron in liver despite up-regulation of heme oxygenase 1, ferroportin, and ferritins. Hepatic heme export activity of Flvcr1a was closely associated with heme biosynthesis, which is required to sustain cytochrome induction. Upon cytochromes P450 stimulation, Flvcr1a(fl/fl);alb-cre mice had reduced cytochrome activity, associated with accumulation of heme in hepatocytes. The expansion of the cytosolic heme pool in these mice was likely responsible for the early inhibition of heme synthesis and increased degradation of heme, which reduced expression and activity of cytochromes P450. CONCLUSIONS In livers of mice, Flvcr1a maintains a free heme pool that regulates heme synthesis and degradation as well as cytochromes P450 expression and activity. These findings have important implications for drug metabolism.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Emanuela Tolosano
- Molecular Biotechnology Center and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
| |
Collapse
|
49
|
Rusconi F, Paganini L, Braida D, Ponzoni L, Toffolo E, Maroli A, Landsberger N, Bedogni F, Turco E, Pattini L, Altruda F, De Biasi S, Sala M, Battaglioli E. LSD1 Neurospecific Alternative Splicing Controls Neuronal Excitability in Mouse Models of Epilepsy. Cereb Cortex 2014; 25:2729-40. [PMID: 24735673 DOI: 10.1093/cercor/bhu070] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Alternative splicing in the brain is dynamic and instrumental to adaptive changes in response to stimuli. Lysine-specific demethylase 1 (LSD1/KDM1A) is a ubiquitously expressed histone H3Lys4 demethylase that acts as a transcriptional co-repressor in complex with its molecular partners CoREST and HDAC1/2. In mammalian brain, alternative splicing of LSD1 mini-exon E8a gives rise to neuroLSD1, a neurospecific isoform that, upon phosphorylation, acts as a dominant-negative causing disassembly of the co-repressor complex and de-repression of target genes. Here we show that the LSD1/neuroLSD1 ratio changes in response to neuronal activation and such effect is mediated by neurospecific splicing factors NOVA1 and nSR100/SRRM4 together with a novel cis-silencer. Indeed, we found that, in response to epileptogenic stimuli, downregulation of NOVA1 reduces exon E8a splicing and expression of neuroLSD1. Using behavioral and EEG analyses we observed that neuroLSD1-specific null mice are hypoexcitable and display decreased seizure susceptibility. Conversely, in a mouse model of Rett syndrome characterized by hyperexcitability, we measured higher levels of NOVA1 protein and upregulation of neuroLSD1. In conclusion, we propose that, in the brain, correct ratio between LSD1 and neuroLSD1 contributes to excitability and, when altered, could represent a pathogenic event associated with neurological disorders involving altered E/I.
Collapse
Affiliation(s)
| | - Leda Paganini
- Department of Medical Biotechnology and Translational Medicine
| | - Daniela Braida
- Department of Medical Biotechnology and Translational Medicine
| | - Luisa Ponzoni
- Department of Medical Biotechnology and Translational Medicine
| | | | - Annalisa Maroli
- Department of Medical Biotechnology and Translational Medicine
| | - Nicoletta Landsberger
- Theoretical and Applied Sciences, Division of Biomedical Research, University of Insubria, Busto Arsizio 21052, Italy San Raffaele Rett Research Center, Division of Neuroscience, San Raffaele Scientific Institute, Milan 20132, Italy
| | - Francesco Bedogni
- San Raffaele Rett Research Center, Division of Neuroscience, San Raffaele Scientific Institute, Milan 20132, Italy
| | - Emilia Turco
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Università Degli Studi di Torino, Turin 10126, Italy
| | - Linda Pattini
- Dipartimento di Elettronica, Informazione e Bioingegneria-Politecnico di Milano, Milan, Italy
| | - Fiorella Altruda
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, Università Degli Studi di Torino, Turin 10126, Italy
| | - Silvia De Biasi
- Department of Biosciences, Università Degli Studi di Milano, Milan 20122, Italy
| | - Mariaelvina Sala
- Department of Medical Biotechnology and Translational Medicine CNR, Institute of Neuroscience, Milan, Italy
| | - Elena Battaglioli
- Department of Medical Biotechnology and Translational Medicine CNR, Institute of Neuroscience, Milan, Italy
| |
Collapse
|
50
|
Maccarinelli F, Gammella E, Asperti M, Regoni M, Biasiotto G, Turco E, Altruda F, Lonardi S, Cornaghi L, Donetti E, Recalcati S, Poli M, Finazzi D, Arosio P, Cairo G. Mice lacking mitochondrial ferritin are more sensitive to doxorubicin-mediated cardiotoxicity. J Mol Med (Berl) 2014; 92:859-69. [PMID: 24728422 PMCID: PMC4118045 DOI: 10.1007/s00109-014-1147-0] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Revised: 02/09/2014] [Accepted: 03/18/2014] [Indexed: 10/26/2022]
Abstract
UNLABELLED Mitochondrial ferritin is a functional ferritin that localizes in the mitochondria. It is expressed in the testis, heart, brain, and cells with active respiratory activity. Its overexpression in cultured cells protected against oxidative damage and reduced cytosolic iron availability. However, no overt phenotype was described in mice with inactivation of the FtMt gene. Here, we used the doxorubicin model of cardiac injury in a novel strain of FtMt-null mice to investigate the antioxidant role of FtMt. These mice did not show any evident phenotype, but after acute treatment to doxorubicin, they showed enhanced mortality and altered heart morphology with fibril disorganization and severe mitochondrial damage. Signs of mitochondrial damage were present also in mock-treated FtMt(-/-) mice. The hearts of saline- and doxorubicin-treated FtMt(-/-) mice had higher thiobarbituric acid reactive substance levels, heme oxygenase 1 expression, and protein oxidation, but did not differ from FtMt(+/+) in the cardiac damage marker B-type natriuretic peptide (BNP), ATP levels, and apoptosis. However, the autophagy marker LC3 was activated. The results show that the absence of FtMt, which is highly expressed in the heart, increases the sensitivity of heart mitochondria to the toxicity of doxorubicin. This study represents the first in vivo evidence of the antioxidant role of FtMt. KEY MESSAGE Mitochondrial ferritin (FtMt) expressed in the heart has a protective antioxidant role. Acute treatment with doxorubicin caused the death of all FtMt(-/-) and only of 60 % FtMt(+/+) mice. The hearts of FtMt(-/-) mice showed fibril disorganization and mitochondrial damage. Markers of oxidative damage and autophagy were increased in FtMt(-/-) hearts. This is the first in vivo evidence of the antioxidant role of FtMt.
Collapse
Affiliation(s)
- Federica Maccarinelli
- Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123, Brescia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|